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The large-scale separation of proteins from equine blood plasma was investigated, as an attempt to 
create a process that would separate multiple proteins. This contrasts to the current state, where 
methods target a single protein at a time. Ion exchange chromatography and ethanol precipitation 
were both used as techniques, due to their use in human blood plasma fractionation and their 
versatility as downstream separation methods. The bases of ethanol precipitation and the underlying 
percentages used were investigated, along with techniques specifically designed to remove albumin. 
Ion exchange fractions were based on those used in the separation of bovine plasma, with a specific 
focus on a 20-fold scale-up in column volume. 
 
The results indicate that ion exchange chromatography is a feasible separation method. Separation 
was able to be carried out, with immunoglobulins in particular easily obtainable from this techniques. 
The overall profile broadly matched that of bovine blood plasma. However, there was considerable 
amounts of buffer required, along with significantly increased column pressure upon scale-up. These 
drawbacks can be overcome, but this may restrict the applicability of the process as an initial step due 
to the expense of buffers and columns that can withstand high pressures. Ethanol precipitations, on 
the other hand, proved effective in separation and would be easier to scale up for an industrial 
process, although requiring flame-proof equipment and facilities at large scale. While issues were 
found with the techniques used to identify the proteins, it was clear that in particular, albumin 
separation methods from the bovine plasma industry would easily be adaptable to equine blood.  
 
From this, a complete process was obtained for use in both existing and new plants. With only three 
sub-categories of proteins commercialised from equine plasma, the scope for minimising waste 
protein was severely restricted. In addition, many of the methods of separation are quite expensive, 
further restricting the number of proteins that could be obtained. However, there is the ability to 
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Chapter 1: Introduction 
 
Blood plasma, the mixture of dissolved proteins in blood excluding cells, has received increased 
scientific attention over the last century [1-3]. While this is partially due to the increased knowledge 
of the medical properties inherent to it, much is also owed to work aimed at separating, identifying 
and characterising the various proteins within it. This has resulted in new treatments for certain 
ailments, such as haemophilia, and created a large industry based on separating certain proteins [4, 
5]. 
 
Knowledge of human blood plasma has been an understandable priority; meaning similar 
understanding of other mammalian systems has lagged behind, with far more basic studies 
undertaken. This is partially because of the decreased economic incentives of obtaining the various 
corresponding proteins. However, this has not stopped large scale production extending to the blood 
plasma of various animals [6].  
 
That is not to say that these plasmas have not received any academic attention. Bovine plasma is the 
most explored, partially due to the quantities available and that proteins such as bovine serum 
albumin (BSA) have research applications in cell culture and as protein standards [7]. Equine plasma 
has been an additional target [8-10]; however this has been to a far lesser extent. This is despite the 
extraction of proteins from equine plasma such as immunoglobulin fragments, as many extraction 
processes are only designed to extract one type of protein [11, 12]. The ultimate result of this is a 
patchwork of different processes abounding, many of which cannot be used in combination. 
Meanwhile, there seems to be little focus on a comprehensive separation strategy. 
 
An example of this is equine chorionic gonadotropin, which is generally produced using 
metaphosphoric acid precipitation [13]. This technique uses harsh conditions at around pH 3 which 
can result in protein deactivation in other proteins, lowering their commercial value. This indicates 
that in this, and other similar processes [10], there are no attempts being made to obtain as many 
products as possible, resulting in a considerable amount of waste. 
 
For these reasons, this thesis focused on equine plasma and the proteins within it. Some identification 
of the plasma proteins was undertaken, but a greater priority was on the separation processes. The 
main objective was to determine which equine plasma proteins could be separated using normal 
industrial techniques. The additional constraint of ensuring as many proteins as possible would remain 




1.1 Blood contents 
 
 
While sequencing and structural studies have been carried out on many equine proteins [14-16], these 
have mostly focused on what proteins are present, rather than the respective quantities of these. 
Some studies have looked at quantities of albumin to globulins [17, 18] with the intent of determining 
the ratio between the two. Proteins that exist in smaller quantities have received far less attention, 
however. 
 
Again, knowledge about human plasma is more advanced in this regard, out of medical necessity. Far 
more factors have been identified and quantified, as there are greater medical and academic interests 
in identifying these. Of particular interest have been clotting factors, which are used as haemophilia 
treatments [5]. Table 1.1 gives an outline of the typical composition of human blood.  
 
Table 1.1: The composition of human blood. Produced with data from [19] and [20]  
Blood Component Sub-Component Sub-amount (%) Amount (%) 
Cells   45 
 Red Blood 44.9  
 White Blood and 
Platelets 
0.10   
Plasma   55 
 Water 49.5  
 Albumin 2.8  
 Immunoglobulins 1.0  
 Fibrinogen 0.2  




 Alpha -1-Antitrypsin 0.2  
 Other 0.8  
 
 
While Table 1.1 relates to human blood plasma specifically, the results of the equine albumin/globulin 
ratios indicate these figures are accurate for horse plasma [17]. What is particularly noticeable is the 
extent to which these two protein families dominate the total protein mass.  This means it can be 
difficult to determine proteins that exist in lower quantities. Exacerbating this is the natural variance 
between individuals, which can be of orders of magnitude in some proteins that exist in smaller 
concentrations [21]. Despite this, there have been some efforts to determine the quantities of similar 




1.2 Industrial separation methods 
 
A number of separation methods exist within the blood plasma industries. There is a clear split in the 
objectives of these. For most mammalian systems, the focus tends to be on extracting a single protein. 
While similar systems exist for human plasma, there is a much greater emphasis on fractionating the 
entire proteome, due to the higher value of individual proteins, as can be seen in modern studies [4, 
5]. 
 
There are three main stages to a separation; capture, intermediate processing and polishing. Capture 
involves ensuring the protein of interest is present, intermediate processing diminishes the presence 
of other proteins and polishing ensures the isolated protein is as pure as necessary. Figure 1.1 
illustrates the way this may work in practice. Each of the following processes is designed to fit into at 





Figure 1.1: A typical broad separation scheme in practice for blood plasma. Based on data from [5]  
 
Cryo-precipitation is the first step in many human plasma processing steps. The reason for this is that 
the cryo-precipitant is merely the precipitants from frozen plasma centrifuged out, and most plasma 
is stored and transported frozen to retain activity. This makes cryo-precipitation extremely easy to 
carry out initially. While investigations have been carried out on human plasma [24], the products 




Cohn fractionation was the first major method used within the industry, being developed during the 
Second World War as a method to separate albumin for medical use [25]. This method involves the 
addition of ethanol at varying concentrations. Precipitations are carried out at low temperatures, with 
the supernatant being exposed to the next ethanol step. The final supernatant contains almost pure 
albumin, although it is common for previous steps to undergo processing to increase the albumin 
yield. 
 
Despite its age, this method is still used consistently in modern plasma fractionation. While it was 
originally a stand-alone method, it has now also been adapted to fit as a polishing stage for proteins 
such as immunoglobulins [26-28]. Other adaptions with different concentrations of ethanol and the 
addition of chromatography have been also used in an attempt to improve the process [29, 30]. 
 
Similar precipitation methods have been used as well, albeit far less extensively and generally in the 
extraction of particular proteins [31]. Occasionally, stand-alone ethanol precipitations and different 
pHs have been used. Likewise, different chemicals, such as ammonium sulphate and caprylic acid, are 
reasonably common precipitants. 
 
During the 1970s and 1980s, however, liquid chromatography began to be used more commonly [32]. 
Chromatography is based on moving a mobile phase – in this case the blood plasma – through a 
stationary phase. The stationary phase is generally made up of a number of beads, which have some 
property designed to assist in separation. For instance, ion exchange chromatography has a number 
of ions bound to the beads, attracting proteins based on charge.  
 
Initially, chromatography proved difficult to undertake, due to problems in ensuring a consistent bed, 
and thus good flow channels. However, there has been a development of more consistent beds, along 
with stationary phases becoming easier to produce [33]. This has eventually provided a powerful tool 
capable of processing large volumes, while also allowing different means of separation. Today, 
chromatography has become the backbone of plasma fractionation, with anion exchange being the 
most used form. 
 
Less glamorous methods have also seen extensive use. Filtration is used both to separate cell matter 
and as a final polishing stage for certain proteins [34, 35]. Because of its antiquity and relatively simple 
separation principle, less attention has been focused on this method. However, it can cope with much 
larger volumes of plasma than many other methods, and plays a key role in product safety by removing 
viral elements that can infect blood.  
 
Likewise, centrifugation is a key part of many separation studies, but is mostly used as a method of 
separation that is used to clarify another method, such as precipitation. For instance, ethanol 
separations often use centrifugation to separate out the precipitate. This is generally considered part 
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of a single separation step, for instance to separate a precipitated protein from the main plasma body. 
This means that little academic interest is generally devoted to it as an independent method [36].  
 
1.3 The aims of this thesis 
 
This thesis demonstrates a method to separate fractions from equine plasma. However, unlike 
previous research, there is an emphasis on ensuring that multiple fractions remain collectable. This 
means that harsh conditions, such as low pH, were avoided.  
 
In addition, large-scale separation should be an achievable goal from this method. While many 
techniques exist that are proven on the small scale, these are often far too expensive to carry out at 
an industrial level, for instance electrophoresis. Thus, methods were only chosen if there was a 
realistic expectation that large volumes could be separated via this method. 
 
New technologies provided an interesting dilemma. On one hand, many provide the means for 
separation that would fulfil most of the other requirements. This is weighted against the factors that 
many, by definition, are less proven at the large scale. Many are also currently unused in industry, 
meaning that introducing them would entail significant expense. For this reason, and that equine 
plasma products generally compete by being fairly cheap, established technologies were used as much 
as possible.  
 
Furthermore, many techniques that cannot be used to separate multiple fractions, for instance affinity 
chromatography, were ignored. While indisputably helpful, these are better used as polishing 
techniques once the bulk of protein fractions have been removed. Techniques that are adaptable to a 
wide range of proteins were instead chosen. The intent of this was to allow any method designed to 
separate individual proteins to be added at the end to the appropriate fraction. 
 
 
1.4 Scope and organisation of thesis 
 
Chapter 2 of this thesis examines the literature based on the various methods of separation and blood 
plasmas in existence, trying to determine what methods are in existence already and could be used. 
Chapters 3 and 4 look at methodologies and results of two different types of separation technique; 
ethanol precipitations for Chapter 3 and ion exchange chromatography for Chapter 4. These two 





Chapter 5 discusses the implications of the results of the previous two chapters, aiming to put together 
a comprehensive separation process at an industrial scale. Chapter 6 looks at various conclusions from 




Chapter 2: Literature review 
 
Research of the current literature was undertaken in order to identify the information currently 
available about equine blood plasma and its separation. The aim of this was to determine techniques 
that could be used or adapted to ensure broad-scale separation. However, information on 
comprehensive separation is somewhat limited, due to certain gaps in the field. For this reason, other 
mammalian systems were examined when they were considered relevant. 
 
In addition, a comprehensive study of separation techniques used was undertaken. Multiple fields of 
bioprocessing were considered for this, because techniques such as chromatography were 
demonstrated to work before being applied to blood plasma. However, as per the constraints of this 
thesis, they were not considered as methods for separation of blood plasma. 
 
2.1 Plasma Types 
 
Human blood plasma is usually to be obtained through volunteers [4, 5], a practice that is obviously 
impossible with animals. Slaughterhouses are common sources of bovine blood plasma, along with 
some less-used types of blood plasma [37-39]. Equine plasma, by contrast, tends to be obtained from 
animals specifically farmed for that purpose, due to the limited consumption of horsemeat in Western 
countries [6].  
 
The result of this is that equine plasma proteins tends to be considerably less accessible than bovine 
counterparts. For this reason, research in them is considerably more limited than for human or bovine 
plasma. Most of this research is based on existing processes, rather than refining them further or 
discovering new opportunities. For many of the most recent trends in the industry, other forms of 
blood plasma are thus essential to consider. 
 
Table 2.1 contains a number of the proteins present in human, bovine and equine blood plasmas, 
along with quantities where known. It is evident from this that human plasma is far better studied. 
Part of the reason for this is that many of the proteins present are noted primarily for their relationship 
with certain diseases or ailments, which are far less studied in cows and horses. For similar reasons, 







Table 2.1: A list of the blood plasma proteins within human (h), bovine (b) and equine (e) plasmas, 
with known quantities of these proteins 
Protein Source Quantity (g/L) Reference 
Albumin    
 h 35-50 [40] 
 b 35 [41] 
 e 30-39 [42] 
Immunoglobulin G    
 h 8-16 [43] 
 b 25 [44] 
 e 10-25 [45] 
Transferrin    
 h 2-4 [40] 
 b 2-7 [46] 
 e 4.3 [47] 
Fibrinogen    
 h 3-4 [48] 
 b 5.0-6.6 [49] 
 e 0.9-2.3 [50] 
Immunoglobulin A    
 h 0.5-4 [43] 
 b 3-7 [44] 
 e 2-3 [45] 
Alpha-2-Macroglobulin    
 h 2 [51] 
 b -  
 e -  
Immunoglobulin M    
 h 0.3-3 [43] 
 b 0.1-0.6 [44] 
 e 0.8-1.2 [45] 
Alpha-1-Antitrypsin    
 h 1.4-2.3 [52] 
 b -  
 e -  
C3 Complement    
 h 0.8-1.2 [53] 
    
 e -  
Haptoglobulin    
 h 0.6-2.5 [40] 
 e 0.3 [47] 
Apolipoprotein A-1    
 h 1.3-1.6 [54] 
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 b -  
 e -  
Apolipoprotein B    
 h 0.7 [40] 
 b -  
 e -  
Alpha-1-acid 
glycoprotein 
   
 h 0.6-1.2 [55] 
 b -  
 e 0.012 [47] 
Lipoprotein    
 h -  
Factor H    
 h 0.1-0.6 [56] 
Ceruloplasmin    
 h 0.2-0.4 [40] 
 e -  
C4 Complement    
 h 0.17-0.33 [53] 
 e -  
Complement Factor B    
 h 0.2 [57] 
 e -  
Prealbumin    
 h 0.16-0.35 [58] 
C9 Complement    
 h 0.04 [57] 
C1q Complement    
 h 0.066 [57] 
C8 Complement    
 h 0.048 [57] 
C5 Complement    
 h 0.05 [57] 
Plasminogen    
 h 0.1 [40] 
Immunoglobulin D    
 h 0.03 [59] 
C1 Inhibitor    
 h 0.19 [57] 
C6 Complement    
 h 0.06 [57] 
C7 Complement    
 h 0.06 [57] 
Complement Factor 1    
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 h 0.04 [57] 
Retinol Binding 
Globulin 
   
 h 0.04-0.05 [60] 
iC3b    
 h 0.01 [61] 
Thyroxin Binding 
Globulin 
   
 h -  
C2 Complement 
Protein 
   
 h 0.03 [57] 
Thrombus Precursor 
Protein 
   
 h 0.002-0.009 [62] 
C-reactive Protein    
 h 0.003 [63] 
Bb Fragment    
 h 0.001 [64] 
C3a Complement 
Protein 
   
 h 0.0002 [65] 
Anit-Testosterone 
Antibody 
   
 b -  
Conglutinin    
 h -  
 b 0.001-0.05 [66] 
 e -  
Gelsolin    
 h 0.24 [67] 
 b -  
 e -  
Kininogen    
 h 0.07-0.12 [40] 
 b -  
 e -  
Prothrombin    
 h 0.05-0.1 [68] 
 b -  
 
2.1.1 Human plasma 
 
While human blood plasma is in many ways the worst comparison due to the widely differing 
requirements, it is also one on which large scale production is fully expanded.  Bovine plasma tends 
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to instead be divided by vital component, as do other animal plasmas. This makes it difficult to assess 
what technologies are generally used, as major variance in the separation method used can occur 
between products. It also demonstrates a fundamentally different set of objectives towards non-
human blood plasma.  
 
It is also interesting to view developments in the human plasma industry, as these tend to anticipate 
similar applications in the animal plasma industry. Examples of this include Cohn fractionation, with a 
bovine variant developed some time later [25, 69], and, more recently, affinity chromatography [6, 
70, 71]. One interesting development is the development of recombinant alternatives to blood 
proteins [31], such as F(ab)2 fragments, that could compete with blood plasma products on a 
commercial level. However, it is unlikely that these will be cost-effective for equine plasma for some 
time.  
 
Perhaps the definitive review of human blood plasma is that of Burnouf [5]. This covers a wide range 
of techniques used in the human plasma industry, complete with a description of extraction of many 
factors. While many of these factors are not relevant to equine plasma, what is interesting is the 
relatively low level of technology for many of the techniques used, with chromatography generally 
the most recent development. This demonstrates the conservative nature of the industry with regards 
to new processes. 
 
Another demonstration of this is the relatively low proportion of blood plasma proteins that are used 
commercially. It has been noted that four proteins (albumin, IgG, Factor VIII and alpha-antitrypsin) 
make up around 70% of sales even in the human plasma industry [72]. This very low proportion 
highlights the difficulty in finding products from blood plasma. 
 
This conservativeness is not without justification, as noted by Curling [73]. His discussion notes that 
because regulators tend to adopt the view that the process is the product, companies are often 
reluctant to introduce new methods into a process. This has a knock-on effect for mammalian blood 
plasmas, due to the fewer genuinely new innovations being produced and proven to work. In certain 
cases, innovations may even occur in the animal plasma industries before human plasma, thanks to 
fewer regulatory requirements.  
 
Disease transfer has also been a historical risk. Past practices have been linked to HCV (Hepatitis C) 
outbreaks [74, 75]. These concerns have restricted development of existing practices for some time 
[76]. It also has served as a reminder of the dangers of poor separation and purification techniques.  
 
Partially as a result of this, most of the recent focus has been on ensuring the safety of any future 
plasma products. Farcet [77] and Lovick [78] are both examples of this, each viewing risks involved 
with reducing hepatitis risk in blood donation. While these are crucial with regard to safe production, 
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they are generally less focused on new methods of separation. This indicates that from an industrial 
perspective, there has no dramatic progress in downstream technologies recently. 
 
 
2.1.2 Bovine Plasma 
 
A few studies have looked at total separation processes in bovine plasma. Talamo [22] was one of the 
first to comprehensively examine the proteins present in the blood plasma. The 2-D map obtained 
was predictably dominated by a few proteins, but nevertheless gave a demonstration of what could 
be expected from a typical mammalian system.  
 
Marco-Ramell [79] took this one step further, removing albumin and immunoglobulins from the 
plasma before running a 2-D electrophoresis gel. However, the focus of this study was on establishing 
the effectiveness of such methods as opposed to determining the proteins left behind. Their study 
thus only provides the maps created by the 2-D gels as useful components for the context of the aims 
of this thesis. 
 
Alonso-Fauste [23] also examined bovine plasma using 2-D electrophoresis, albeit in a more limited 
context. Their results were more concerned with mastitis, and identifying differences between healthy 
bovines. This limited the usefulness of the 2-D maps of the gels obtained. 
 
A common feature was that obtaining a bovine protein map was not a primary goal in any of these 
studies. This demonstrates the lack of perceived incentive in comprehensive separation strategies. 
This is partially due to the fact that there are so few proteins consistently separated from animal blood 
plasmas.  
 
Another issue many of these papers have in common is that protein identification is generally not 
carried out. This applies particularly in the cases where albumin and immunoglobulins are removed. 
This seems unusual, as in these studies, identifying other proteins would be made considerably easier. 
Such identification needs to be a feature of further research. 
 
2.2 Equine plasma 
 
There have been few comprehensive studies on equine blood plasma. However, certain proteins such 
as immunoglobulins have been identified from the plasma. This allows for some examination of the 
components, if not of a comprehensive strategy for separation of these components. A white paper 
published some time ago by the USDA has noted that only a few products have been approved for 
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use, the majority of which are immunoglobulins [80]. However, this only refers to those designed for 
human consumption, as many extracted proteins are used for other applications. This means that 
many extracted proteins were not included in their count because they fell outside the parameters of 
the investigation.  
 
One of the earliest attempts to determine the plasma contents was that of Keay [81], who examined 
the blood sera of cattle, sheep and horses. This gave the electrophoretic positions of albumin along 
with alpha, beta and gamma globulins relative to each other. This work was expanded on by Riond 
[42], who gave more precise quantities of these proteins. However, the lack of molecular weight 
testing meant that these could only be identified as electrophoretic fractions. 
 
Other attempts have followed similar paths, using molecular mass as a point of difference instead of 
isoelectric point. Bokina [82] detailed protein bands of various masses and intensities, however the 
proteins found were not characterised. Similar work was carried out by Alberghina [17] and 
Quartuccio [18], with some identification of the proteins carried out. Neither paper contained more 
than passing mention of separation of the blood plasma. 
 
On the other hand, there is a considerable amount of material covering the use of separation in the 
field of drug testing [83]. Two factors limit this applicability in industrial use for production. The first 
is scale, with all drug testing being practiced at much lower volumes than any industrial separation 
technique. The other is that, other than specific proteins being tested for, the other contents of the 
blood are generally not being tested for. This tends to result in antibody recognition and affinity 
systems that give poor results for overall separation. 
 
This lack of information means that much of the information that can be used has to be put together 
through individual proteins rather than entire plasma information. A brief summary of some of the 
proteins and methods used for separation is given in Table 2.2. This demonstrates the paucity of 











Table 2.2: A brief summary of the functional methods used to separate equine proteins 
Protein Method Reference 
Albumin + globulins electrophoresis [18] 
eCG magnetic ion-exchange chromatography [10] 
Albumin + globulins electrophoresis [17] 
IgG ammonium sulphate + caprylic acid 
precipitation 
[8] 
IgG F(ab)2 IEC/ affinity chromatography [70] 
IgG caprylic acid precipitation [84] 
IgG caprylic acid precipitation [85] 
IgG caprylic acid/ pepsin [86] 
IgG F(ab)2 caprylic acid/ammonium sulphate 
precipitations 
[87] 
IgG aqueous 2-phase system [88] 
IgG Ethanol precipitation [31] 





There are several families of immunoglobulin protein, the most common of which being IgG. The 
common structure of IgG molecules includes two heavy chains is made of units each around 50 kDa in 
mass, and two light (and active) chains made up of units around 25 kDa each. These generally exist in 
pairs, as demonstrated in Figure 2.1. These also generally have one of the highest pI values of any 
blood protein, with values generally between 6 and 10 [89]. This increases the capability of separation 





Figure 2.1: A simplified diagram of the structure of IgG. Created with information from [90] 
 
Immunoglobulins (Ig) provide immune response to specific ailments. For this reason, they are 
excellent components of passive vaccines. Antibodies for the rabies virus are often purified from 
equine blood and used as a cheaper alternative to similar human antibodies in poorer nations [9, 12, 
70, 91]. Meanwhile, snakebite immunoglobulins are also used in a similar manner [8, 11, 86, 88]. These 
traits make this class of protein probably the most studied of equine blood proteins. Furthermore, 
they are likely to have the highest commercial value of any equine blood waste product, providing 
that they are not already being produced. For this reason, they are probably the best way to improve 
the value of an industrial equine blood separation, making them a critical part of this investigation. 
 
Consequently, more methods for separating immunoglobulins have been explored than for most 
other proteins. Ammonium sulphate precipitations have been historically common [6, 86, 92], 
although caprylic acid has emerged as an alternative [93-95]. Methods such as adapted Cohn 
fractionations have also been considered, with the use of ethanol [31]. 
 
Increasingly, chromatography has become the method of choice for separation. Affinity 
chromatography using Protein A and Protein G matrices are most common, because of the yields 
achieved [96]. Alternatives have also been used, with ion exchange [12, 70, 97, 98] and even metal 





Albumin is the largest protein component of blood plasma, including in equine plasma. Figure 2.2 
illustrates its chemical structure. Its role is as a transport protein, with a large number of bonding sites 
able to convey crucial ions and proteins through the blood. With a molecular mass of around 70 kDa, 
it is relatively small, but has no easily defined subunits [100]. Its pI is considerably lower than that of 
immunoglobulins, at around 5. 
 
Figure 2.2: The full crystal structure of ESA. Image from the RCSB PDB (Protein I.D: 3V08). Protein 
structure determined by [101] 
 
ESA is normally extracted using electrophoresis at an analytical level. This is not adequate for larger 
scale separation, as applying a charge gradient over large amounts of material is not practical. 
 
At larger levels, Cohn fractionation adaptions are the most prominent methods for obtaining albumin 
[102, 103]. The original method has since been adapted for bovine plasma [104]. Despite some 
adaptions, the bulk of the process is still the same as that originally used by Cohn. Some 




For BSA, there has been a movement against using ethanol precipitations due to safety concerns of 
virus transmission [105]. Heat shock has instead been preferred because of the higher likelihood of 
virus removal. This has been reflected in the equine industry, where most ESA is produced similarly.  
 
ESA has not been extensively explored as a veterinary tool [106], which has helped contribute to a lack 
of interest in it. Most applications are as a research substitute for BSA. However, it has some value in 
research roles [14], indicating that it may still be worthwhile separating this as a by-product of some 
other process. Belli [106] also noted its use as a tool in some animal health situations, however these 
are likely to be lower value than immunoglobulins. 
 
2.2.3 Other proteins 
 
eCG (equine chorionic gonadotropin) has applications as a supplement for a number of agricultural 
animals [107-110]. This protein exists in much smaller quantities in plasma and has a similar molecular 
mass to ESA at around 61 kDa, making fractionation a more difficult process. Processes to fractionate 
this have traditionally involved metaphosphoric acid precipitations [13], which have replaced 
chromatographic separations [111]. This presents problems, because the lowering of the pH 
potentially denatures other proteins. However, this is a key protein to be noted for potential 
production for any equine blood processes not already purifying it. 
 
Fibrinogen has also been investigated, although this has partially been as a veterinary tool for analysis 
of equine health [112]. Scaled-up separation of fibrinogen has not been looked into, as it is unlikely to 
have commercial prospects in the foreseeable future. Porcine fibrinogen has been demonstrated as a 
meat additive [35], but this is unlikely to act as a good market for similar equine products. 
 
A number of the more abundant proteins have also been examined, although primarily in terms of 
analytical systems for medical purposes. Haptoglobin and transferrin have both been used as medical 
markers of health [113]. Some medical applications have been found for human transferrin [114], but 
this is unlikely to extend to horses in practical applications because the diseases and applications are 
rare and complex respectively. Few other proteins are mentioned outside of comparisons between 
healthy and unhealthy horses, and none of these have had any real attention devoted to purification.  
 
 
 2.3 Existing Separation Methods 
 
Blood plasma separation has been based on traditional methods used within the downstream 
bioprocessing industry. However, there are two significant distinguishing points; the volume of plasma 
processed, which is generally at the high end of purification processes, and that the upstream inputs 
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cannot easily be changed through modifications within the control of the purification group. These 
factors limit the application of certain techniques that would otherwise be usual. 
 
Separation practices can vary widely, depending on the type of plasma being used and the desired 
product. As mentioned previously, human blood plasma has been the best analysed with a 
comprehensive strategy in mind, and a diagram of a practical separation scheme for this is shown in 
Figure 2.3.  
 
One interesting aspect of Figure 2.3 is the uniformity of techniques. The vast majority of these proteins 
are separated by some combination of ethanol precipitation, chromatography and filtration. This 
contrasts with the equine industry, in which a large number of differing methods exist. There are 
distinct issues with using this system in an equine context, namely that the vast majority of proteins 
separated in this are not generally commercially produced. However, it provides a keen insight into 
the types of techniques that could be expected to be viable at an industrial level. 
 
In this particular scheme, cryo-precipitation is the first technique used. However, its application is 
limited to the beginning of any given process, because blood plasma is generally frozen for storage. 
This means that most studies are based on exploiting this differently, rather than explicitly improving 
the technique. In addition, the only separated protein that may be valuable in equine systems is 






























Various forms of filtration has a long history in blood plasma studies, primarily as a way to ensure the 
safety of blood products. Instances of nanofiltration use can be seen in a few studies [34, 77, 115, 
116], along with virus removal [77]. This role has diminished as other separation methods have 
become available; however filtration still is used as a strategy. Ultrafiltration, on the other hand, tends 
to be used for clarification of precipitates [5, 11]. 
 
A variant method was tested on human plasma, involving ultrafiltration combined with centrifugation 
[117]. This proved effective at obtaining low molecular mass proteins. A few of these are currently 
useful from equine plasma, such as light IgG chains. In a similar vein, Pares [35] used a membrane 
filtration system as the final stage of their separation of porcine albumin. 
 
Increasingly, filtration systems are expanding from their traditional purposes, with the advent of new 
membrane technologies. With membranes increasingly being developed to allow separation by means 
other than size exclusion, filtration technology may become more important to the industry. Although 
the principles of separation are quite different, aspects of filtration such as scale-up and anti-fouling 
will need to be further studied.  
 
2.3.2 Centrifugation  
 
As previously mentioned, centrifugation has been used reasonably extensively in the blood plasma 
industry [118, 119]. This has mainly come in the form of separating precipitates [25, 119], or in 
combination with filtration [118]. The flexibility and low expense mean that it is a popular technique 
in downstream processing. 
 
The main disadvantage of centrifugation, as noted by Voisard [120], is that it is difficult to adapt a 
centrifugation technique to suit any situation. This has resulted in centrifugation not being seen as a 
stand-alone operation within downstream separation.  In addition, centrifugation has had increasing 
competition from membrane technologies [121]. It is still likely that centrifugation will continue to be 
used in industrial processes, due to its use in existing processes in which it acts as a secondary part of 







Precipitation is well explored within the plasma industry, with a wide number of applications noted. 
These schemes avoid many of the problems associated with chromatography, such as difficult scale-
up, complex operation and the additional flow-through of buffer. Various precipitation means have 
thus been developed both for isolating certain proteins and multi-protein fractionation schemes. 
 
Cohn fractionation is the oldest of the major methods. It relies on multi-stage ethanol concentrations 
in low temperature blood plasma to separate albumin, generally giving good purity [25]. Yield is less 
outstanding, but can be improved by reprocessing early fractions. This process is still fundamental to 
the blood plasma industry, with most methods of obtaining albumin based on the principles this 
established [4]. In addition, many of the earlier precipitations are named and referred to in literature 
by the number of the stage, for instance Fraction I, Fractions II + III.  
 
Despite the advantages of this separation, investigation into the precise steps have been limited [4]. 
Such precipitations rely on a number of factors separate to ethanol percentage being exact, such as 
temperature, pH and salt type and concentration. This makes them particularly difficult to study and 
critique, due to the number of factors that have to be optimised. While Cohn fractions have shown to 
be effective, they are not without purity and/or yield issues, implying that there may be ways to 
further optimise them. 
 
Some processes have been designed with this intent, with variations in the ethanol percentages [29] 
and alternative procedures in place of certain steps [26]. Many of these methods have taken hold, 
with the methods used by Kistler [29] now forming the basis of separation used by companies such as 
Commonwealth Serum Laboratories, based out of Melbourne. This study has not retested the 
underlying basis of the ethanol levels used, however.  
 
Other processes have had different uses of ethanol precipitations, generally relying on one or two 
steps instead of the full-scale instances of Cohn fractionation [27, 31]. These methods are often part 
of wider separation strategies however, as opposed to the stand-alone methods of Cohn and others. 
What is interesting about them is that they can be used to obtain proteins such as immunoglobulins 
and fibrinogen, which is part of the reason that Cohn fractionation is still used in modern industry. 
 
A study into the effects of pH was undertaken by Yoshizawa [122]. This study altered pH levels during 
pH the precipitation of particular proteins, among them BSA. There was an appreciable difference in 
composition and quantity at differing pHs, but the total impact was limited. This indicates that pH is 
generally of low importance in the actual precipitation, with protein activity more critical. It is also 
worth noting that the pH range tested was only from 4 to 7; a small, albeit commonly used, area. This 





Other precipitants are also used. Ammonium sulphate precipitations are particularly common in the 
context of purifying immunoglobulins [11, 35, 98, 123]. These are occasionally used in conjunction 
with pepsin in order to instead obtain the active F(ab)2 fragments. These have the advantage of being 
simple, quick and easy to scale up, much like ethanol precipitations. The largest issue with these 
restricting them in a general separation strategy is the low pH and salting out conditions which are 
not generally conductive to other proteins’ activity.  
 
There have been questions about the necessity of pepsin in the F(ab)2 process. Morais [86] noted that 
these digestions act best at pH levels below 3, which is not conducive to extracting other proteins. The 
reduction of yield caused by the digestion was also noted in the investigation. The other key 
disadvantage is that, like some ethanol precipitations, purity of product can be low at only 30-60%. 
This generally means additional processing steps are needed on top of the precipitations. 
 
An alternative of caprylic acid precipitations has also been used for immunoglobulin precipitation [8, 
87, 124, 125]. This is partially as a response to the low purity of the ammonium sulphate precipitations. 
These have the additional advantage of generally requiring fairly mild pH conditions outside of 
digestion, while maintaining yields at around the 65% mark [87]. 
 
One of the key limitations of caprylic acid precipitations is that of scale [95]. Although this study 
achieved very respectable yields of about 86% or above in equine plasma, the authors noted that 
constant agitation was required to achieve this, with the recommendation of improving centrifugation 
and filtration technology. Other studies have noted the difficulty of removing the precipitate [87]. 
While this may be the case, it is worth noting that mixing scale-up is typically easier to undertake than 
chromatography.  
 
Eursakun [8] attempted to combine the two processes, using a combination of ammonium sulphate 
and caprylic acid to improve the separation. This attempt was unsuccessful, as the combined use did 
not provide any increased isolation. Interestingly, the comparative studies carried out between the 
two methods indicated that caprylic acid was more effective, however this could be reflective of the 
specific conditions chosen.  
 
Morais [94] took a different approach, examining the precipitation of both BSA and immunoglobulins 
in bovine plasma. This proved moderately successful, although immunoglobulin purities and yields 
were lower than for single-protein methods. They also indirectly noted the ability for this to be used 
in equine plasma, with ESA replacing BSA as the product. This demonstrates the practical applications 
of this method, although no scale-up was attempted in this study.  
 
Raweerith [126] originally demonstrated the potential effectiveness of caprylic acid precipitations 




to extract immunoglobulins. A reasonable recovery of 66% was achieved, and the authors believed it 
compared favourably to other techniques at the time. It is worth noting that at the time, affinity 
mediums were more costly than at present. Since this was noted as the most effective method even 
then, this may affect the usability of this technique in a contemporary setting. 
 
Some experimental procedures have tried to take advantage of principles within affinity 
chromatography by carrying out affinity precipitations [127]. These are designed to separate various 
materials without the difficulties and expenses of using chromatography. While this still requires the 
use of the specialist materials of affinity chromatography, it avoids the issues in flow rates and high 
pressures that impact chromatography. The disadvantage to these techniques is that, being affinity-
based, they are poor for comprehensive separation. 
 
Metaphosphoric acid precipitations, as mentioned previously, are often used for eCG separations. 
These precipitations reduce the number of steps required to a minimum, but the base method is dated 





Chromatography has been used extensively for some time now, and is a cornerstone in the blood 
plasma industry [5]. Since the 1980’s, when materials became cheap enough to use in large enough 
quantities, this method’s high purity, good flows and adaptability to scale-up have meant that few 
downstream processes are now carried out without it.  
 
Ion exchange chromatography is of particular note, being the first to be properly developed, and still 
the most used in downstream processing. There have been claims that it can be used well in all three 
stages of processing [128], which highlights the versatility of the process. 
 
In human plasma, IEC is used as part of a process to obtain many different haemophilia treatments 
and coagulation factors, as shown in Figure 2.2. Many of these are irrelevant when it comes to equine 
plasma, as haemophilia treatments are not generally required for equines. What IEC does provide is a 
reliable tool to examine and separate a protein mixture, regardless of the stage of separation. This 
assumes that affecting factors can be accounted for. 
 
There has been some interest in examining pH as a factor of IEC, but one study that found key 
characteristics for equine plasma was Moure’s [27]. This paper looked at separating bovine plasma 
with both a pH and salt gradient. Interestingly, similar results were achieved in each case. This may 




consequences. It would enable a clearer connection between methods using differing pHs, whilst also 
avoiding potentially negative effects of pH extremes. 
 
The other interesting feature of Moure’s investigation was that it was one of the few to examine 
animal plasma separation without a goal of extracting a single protein or group of proteins. This gave 
it a global view many other papers do not have, with a larger focus on what could be obtained from a 
broader separation method. While key proteins were not extracted from the plasma, several were 
identified and salt gradients giving sharp peaks were also noted. 
 
Other uses of ion exchange have been noted in production of immunoglobulins, albumin and eCG [13, 
85]. Even though not all of the results were the most optimal obtained, the range of proteins it has 
been used for demonstrates that this technique is crucial to consider for a comprehensive separation 
process. 
 
Affinity chromatography has increasingly become an alternative, with a large range of investigations 
into its use in blood plasma [71]. This method is not practical for a comprehensive separation strategy, 
but it is a viable option for obtaining certain proteins. There have been concerns about the conditions 
used being too extreme, but there is little difference between these conditions and the alternative 
means generally required for these proteins. 
 
One of the most common uses of affinity chromatography is in immunoglobulin separations. Protein 
A and G separation techniques have been well established in a number of investigations [96, 129, 130]. 
These techniques are known for having high yields and selectivity, but also sometimes harsh 
conditions [131]. While there is strong competition from other methods, this is seen as the gold 
standard for purification of immunoglobulins. 
 
Other blood plasma applications are considerably less common. A recent study demonstrates the use 
of affinity chromatography for human glycocalicin [132], but this is not a protein likely to be extracted 
from equine plasma, because it is used for an unusual human illness. A method separating Factor VIII 
has similar issues [133]. The high costs and low regeneration that these columns traditionally have 
[129] means that this is unlikely to be an effective method outside of clearly established uses. 
 
Various other forms of chromatography also exist, although these are less used in blood plasma 
processing. Hydrophobic interactions chromatography (HIC) is an example of this, with well-developed 
uses in protein separation [134]. The biggest issue with HIC in practice is that many of the same 
functions can be performed by precipitations instead [94]. For instance, caprylic acid precipitations 





Size exclusion chromatography has had some use, but is restricted in general applications [135]. The 
reason for this is the extensive use of ultrafiltration, which at appropriate pore sizes can achieve 
exactly the same outcomes as SEC. However, filtration has fewer of the issues that limit scale-up, 
making it a much more valuable technique at the industrial level.  
 
Metal affinity chromatography has been tested for separating immunoglobulins [99]. While this is 
somewhat effective, it is generally impractical in large scale production. This is because of the 
additional steps required of metal immobilisation [98], which is difficult to undertake given the volume 
of plasma and thus the volume of ions this requires. It is thus unlikely that such a technique will be 
effective at an industrial scale. 
 
Despite its abundance in plasma separation, chromatography is not without issues. It is generally the 
most costly of the methods, particularly in terms of capital costs, and requires the most technical 
knowledge [136, 137]. Due to a number of factors, this information can be difficult to obtain.  Many 
published methods, for instance, do not relate the reasons for the pH selected in IEC, unless these are 
being specifically tested. This could be because of a lack of desire to carry out the extensive and 
tedious work pH testing would require. This makes comparison difficult between methods as it cannot 
easily be determined what factor is most responsible for the results achieved in each study. 
 
Furthermore, chromatography is not necessarily well-suited to industrial scale work. There have been 
debates about its effectiveness [73, 118, 136-138], primarily centred on the cost, time and complexity 
of chromatography. This is part of the reason ethanol precipitations are often more popular, as they 
avoid many of these problems. However, as Azevedo [137] notes, chromatography has carved out a 
niche of being able to resolve many intermediate purifications in a single step. This is something that 
no competing technique has demonstrated consistently. 
 
Curling [73] noted that process improvements in the bioprocess industry have primarily been in the 
upstream sections. Because this is less relevant for the blood plasma industry, gains have been more 
modest. At the time of his review, improvements to downstream processes were beginning to be 
investigated. Since then, continuous chromatography has been investigated in more detail [139]. The 
largest obstacle to this proceeding is the requirement to convert all operations within a given process 
to continuous operation, a significant upfront expense for a company.  
 
2.3.5 Membrane separation 
 
With the debate and search for alternatives to chromatography, membrane separation has received 
increasing attention over the past decade. The technology is itself not new, with previous research 




chromatography into membranes mean that this technology should be considered seriously as part of 
a separation strategy. 
 
Size-exclusion was the first major principle to be incorporated into a membrane mechanism [140]. 
However, more recently ion exchange, hydrophobic and affinity membrane media have all been tested 
[141-143]. This demonstrates the clear intention to use the principles currently demonstrated through 
chromatography, while replacing the less desirable characteristics that packed beds have given. 
 
There are some promising signs about the development of membrane technology. Lu [144] noted that 
membrane replacements for hydrophobic interactions chromatography took less time and consumed 
considerably less volume than standard columns. While hydrophobic interactions chromatography 
has limited applications in blood processing, this indicates the potential improvements membrane 
technology could bring. 
 
Although there is certainly potential in this area of technology, the technology often has lower binding 
yields than that of chromatography [142]. In addition, there is little demonstrated application of these 
to separate blood proteins. A study by Wang [91] showed an application in separating bovine thrombin 
from blood; however this was carried out at very small volumes. For this technique to be considered 
successful difficulties such as fouling, electric stimulation and pressure would have to be solved, thus 
it is clear that this is not yet ready for application within the blood plasma industry. An older study by 
Bayramoglu [145] has similar flaws. These factors indicate that membrane separation in its most raw 
form is not yet suitable for application within the blood plasma industry. 
 
2.3.6 Other techniques  
 
While other technologies have been developed, many have significant issues to overcome, particularly 
scale. A method to separate eCG using adsorbents has been tested at the pilot scale [10]. This method 
has been tested at different scales, which is unusual in itself; however there is less evidence to 
demonstrate how it might perform at a higher scale-up. Many studies do not test scale-up to this 
extent, which may well be because the proteomics field is often the main innovator in new separation 
methods. This means that many such methods are designed for analytical investigations rather than 
industrial separations 
 
The problem with this approach is that many techniques that work well at the small scale are either 
ineffective or far too expensive to carry out on a large scale. For this reason, new techniques should 





With chromatography generally seen as expensive, other options have been looked into. This applies 
especially in non-blood plasma industries, where there is more control over the inputs. Many of these 
are unlikely to be suitable for use within the blood plasma industry, as the inputs to the process are 
less able to be controlled. For instance, there is no record of using crystallisation to separate proteins 
from blood plasma. 
 
Some studies have looked to improve chromatography rather than replacing it altogether. Przybycien 
[136] examined the possibility of fluidised bed chromatography to replace traditional packed beds. 
However, Curling [73] and Nfor [146] emphasised that this would be unlikely to replace traditional 
chromatography for some time. 
 
The use of aqueous two-phase systems has been suggested as an alternative to chromatography [137, 
147]. Nevertheless, this is as a general recommendation for the pharmaceutical industry rather than 
specifically for blood plasma fractionation. Vargas [88] managed to go one step further, separating 
immunoglobulins from equine plasma using this system. This achieved similar yields but lower purities 
than a comparison with caprylic acid. This indicates the technology is not yet ready for large-scale use. 
 
2.4 Techniques investigated in this work 
 
In spite of the efforts to find more cost effective or efficient means of separation, Azevedo’s [137] 
statement that no other method resolves as many separation steps as chromatography still holds true. 
This explains the relatively low use of more recent technologies within large scale blood separation 
strategies and further supports the reason not to include new technologies in an expanded system.  
 
Chromatography was used for a large number of applications within the blood plasma industry. For 
this reason, it was one the techniques examined for separation of equine plasma. Specifically, ion 
exchange chromatography was the main focus, due to its long history and excellent adaptability to a 
separation strategy. While ion exchange membranes are becoming increasingly studied, they are not 
yet in a position to be used for large-scale separation. 
 
Due the amount of literature on them, ethanol precipitations are the other key area worth exploring 
for a broad separation strategy. These generally provide the gentlest forms of separation available, 
with a minimal impact on the other proteins. Because Cohn fractionation still has a large influence on 
blood plasma processes, the technique is also likely to be familiar to industry. This makes this method 
an excellent candidate for allowing industry to successfully separate a larger number of different 




Chapter 3: Separation of Equine Plasma by Ion Exchange 
Chromatography 
 
As discussed, chromatography remains a dominant part of downstream separation methods despite 
the various flaws it possesses. For this reason, it was one of the processes examined more closely for 
advanced separation. Moure [27] demonstrated appropriate salt gradients for bovine plasma while 
using ion exchange chromatography. Because of the similarities between blood plasmas and the 
versatility of anion exchange chromatography, these were considered the starting point for 
investigation. However, scale up work was considered a larger priority. All work was carried out at the 
6th floor School of Biological Sciences Laboratories at the University of Canterbury. 
 
3.1 Materials and Equipment 
 
Equine blood plasma was obtained from Bioniche (now Vetriquinol, Armidale, NSW, Australia) and 
was frozen at -18°C until required. Before use, this plasma was thawed overnight in a 4°C fridge while 
buffers were prepared on the day of chromatography. Analytical grade Tris (AppliChem, Darmstadt, 
Germany), NaCl (Merck KGaA, Darmstadt, Germany) and HCl (Merck KGaA) were all used in the ion 
exchange buffers. These were solubilised in deionised (MilliQ) water and had pH measured with a 
Denver International UltraBasic pH meter (Denver Instrument, Bohemia, NY, USA). For the phosphate 
buffer saline (PBS) NaCl, KCl, Na2HPO4 and KH2PO4 (all Merck KGaA) were used. Blood was spun down 
on a desktop centrifuge (Eppendorf Centrifuge 5415 R, Eppendorf, Hamburg, Germany). 
 
Chromatography took place with 1 mL and 20 mL Sepharose Q Fast Flow columns purchased from GE 
Healthcare (Little Chalfont, UK). The 1 mL columns were used on an AKTA-Start liquid chromatography 
system (GE Healthcare), using UNICORN Start-1 software (GE Healthcare). No fraction collection took 
place at this step. Meanwhile, the 20 mL columns were run on an AKTA-10 machine while being 
controlled by UNICORN 5.31 software (both GE Healthcare). A GE Frac-950 fraction collector was used 
in this case (GE Healthcare). 
 
For post-chromatographic investigation, a LABCONCO FreeZone 2.5 freeze-dryer (Labconco, Kansas 
City, MO, USA) was used, while concentrations were measured on a Nano-Drop ND-1000 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For gels, NuPAGE 4-12% Bis-Tris 
Midi gels were purchased from Novex (Thermo Fisher Scientific), along with NuPAGE LDS Sample 
Buffer, NuPAGE reducing agent, SDS running buffer and Novex Sharp pre-stained protein standard (all 
Thermo Fisher Scientific). These gels were stained with Coomasie Blue stain and images captured using 
a GE ImageQuart LAS 500 (GE Healthcare). The mass spectroscopy was carried out with ammonium 
hydrogen carbonate (Merck KGaA), acetonitrile (Thermo Fisher Scientific), dithiothreitol (Sigma 
Aldrich, St. Louis, MO, USA) and iodoacetimide (AppliChem) with trypsin (Sigma Aldrich) and formic 





3.1.1 Chromatographic preparation 
 
A 200 mM Tris stock solution was made and had its pH adjusted to approximately 7.4 with 
concentrated HCl. This stock was used to make the start buffer of 20mM Tris and the running buffer 
of 20 mM Tris and 1000 mM NaCl. Both were adjusted to pH 7.4. These were filtered using a 40 µm 
filter and degassed for 10 minutes.  
 
In preparation for the chromatographic run, the chromatography system was washed with filtered 
and degassed MilliQ water, followed by start buffer. The column was then washed and regenerated 
with one 5 CV step of start buffer, one 5 CV step of running buffer and finally with a second 5 CV start 
buffer step. Meanwhile, the defrosted equine blood plasma was centrifuged at 4°C and 8000 g for 5 
minutes before being injected onto the column. 
 
3.2 Running steps 
 
The first chromatography was carried out on a 1mL column, aiming to use the salt gradients 
established by Moure [27]. These levels were read to be 0, 50, 100, 170 and 350 mM of NaCl. In 
addition, a 1000 mM NaCl step was added at the end of these steps. Each step was allowed to proceed 
for 5 CV, while 100 µL of blood plasma was used as a sample. The results of this are shown in Figure 
3.1.  
 
Having proof of concept, these steps were repeated on a 20 mL column. The sample size was increased 
to 2 mL to reflect this, while the linear velocity of the elution was altered from 250 cm/h to 240 cm/h 
to avoid exceeding the column pressure limits. All other factors were held the same. The results of 
this can be seen in Figure 3.2. 
 
3.3 Post chromatography 
 
The eluent was collected within 50 mL falcon tubes. The protein-containing fractions were snap-frozen 
to -80°C before being freeze-dried at -46°C and 0.018 kPa until all liquid was removed. The precipitate 
was then washed and dissolved in PBS (137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, and 1.8 mM 
KH2PO4), with the concentration of the redissolved precipitate being measured by UV absorbance. 
Samples from this were then taken, reduced and heated to be run on a sodium dodecyl sulphate 
polyacrylamide (SDS) gel. This was run at 200 V for 40 minutes after loading. This gel was then stained 

















Figure 3.2: Results using the initial salt gradients from Moure [27] on a 20 mL column. Gel lanes are 
as follows (1) Protein standard; (2) Blood plasma; (3) 1:50 blood plasma dilution; (4) Protein 
standard; (5) Peak 1; (6) Peak 2; (7) Peak 3; (8) Peak 4; (9) Peak 5; (10) Protein standard. Numbers on 




With these results obtained, separate variations were carried out. The first of these related solely to 
the length of elution for the various factors and involved increasing the time of elution until baseline 
UV absorbance was reached between peaks. This was once again tested on a 1 mL column and then 
scaled up to 20 mL columns. The elution volumes required to reach baseline UV absorbance are given 










Table 3.1: Modified lengths of salt gradients 









In addition, the concentrations of salt were altered. This was undertaken by experimenting with 
separate salt gradients in 1 mL columns while adjusting the quantities required. A key focus was 
ensuring that the peaks gave as short as elution lengths as could be achieved. The salt levels that best 
provided that are given in Table 3.2. 
Table 3.2: Alternative salt levels for use in anion exchange chromatography with associated lengths 
of elution 









It was noted during this process that a final salt concentration of 500 mM of NaCl and the associated 
conductivity achieved essentially identical results to the previous high point of 1000mM. Therefore, 
from this point the running buffer was made with 500 mM NaCl instead. This can be seen in Figure 




Figure 3.3: Chromatography carried out at the appropriate salt gradients determined in Table 1, with 
an associated gel. Lanes of the gel are (1) Protein standard (2) On sample at 1:50 dilution (3) Peak 1 
(4) Peak 2 (5) Peak 3 (6) Protein standard (7) Peak 4 (8) Peak 5 (9) Peak 6 (10) Peak 7 (11) Protein 
standard. Numbers on the side indicate the molecular weights of the standards 
 
3.4.1 Mass Spectroscopy 
 
Some of the protein bands from the accompanying gel were removed using a knife and sliced into 
small cubes. The Coomasie Blue stain was then removed from the gel using an initial incubation at 
room temperature with 50% acetonitrile for 30 minutes and two further periods of incubation at the 
same temperature with pure acetonitrile for around 10 minutes. After each period, the acetonitrile 
was removed.  
 
10 mM of dithiothreitol in 100 mM ammonium hydrogen carbonate was then added to the gel pieces 
and the mixture was incubated at 56°C for 30 minutes to remove any disulphide bonds within the 






55 mM iodoacetimide in 100 mM ammonium hydrogen carbonate was then added to the gel pieces 
to prevent the disulphide bonds reforming, and the samples were incubated in the dark at room 
temperature for 20 minutes. After another acetonitrile wash, a protease buffer consisting of 1 part 
100 mM ammonium hydrogen carbonate: 1 part acetonitrile: 8 parts MilliQ with trypsin enzyme added 
at a concentration of 0.013 mg/mL was added to the gel pieces and the mixture was incubated 
overnight at 37°C. The following day, an extraction buffer consisting of 1.8 µL 90% formic acid, 670 µL 
acetonitrile and 328 µL MilliQ was added in 120 µL quantities to the gel pieces. This was then 
incubated at 37°C for 15 minutes. This liquid was then removed and freeze-dried, and the solid 
remains were dissolved in formic acid.  This mixture was then sent to the Chemistry Department of 
the University of Canterbury for mass spectroscopy analysis. 
 
3.4.2 Optimisation of chromatographic factors 
 
Given the importance of ensuring that this process would operate correctly on a large scale, an 
investigation was undertaken to test how various factors affected the resolution and peak purity. Flow 
rate, length of elution and sample size were all identified as factors of relevance and each was tested. 
 
To test elution speed, the chromatographic process was carried out at 60, 150 and 240 cm/h 
respectively on the 20 mL column. Higher superficial velocities were not attempted as these were not 
able to be carried out within the column pressure limits. The results of these comparisons are shown 
in Figure 3.4.  
 
To test sample size, this factor was adjusted to 5 and 20 mL in the 20 mL column. The process was run 
at 240 cm/h, with all other factors being held constant. No fractions were collected for this process. 
The results for this comparison are given in Figure 3.5. In addition, the area underneath the curves 














Table 3.3: The effect of increased sample size on the UV detection. Note that * denotes a peak that 






5 mL sample 
(mAU*mL) 
Proportion larger 
than 2 mL sample 
20 mL sample 
(mAU*mL) 
Proportion larger 
than 2 mL sample 
0 13520 39920* 2.95* 108500* 8.03* 
50 10660 24710 2.31 44270 4.15 
100 14170 32210 2.27 110710 7.81 
170 33500 65110 1.94 113680 3.39 
340 18150 38360 2.11 82440 4.54 
 
The effect of shortening the lengths of elution was done in a similar manner to the way in which the 
data in Table 3.3 was obtained. In this case, however, the data was obtained from a standard run at 
240 cm/h and 2 mL sample size. Fractions of the overall length were calculated and the area under 
the curve was recalculated over these fractions. These areas are given in Table 3.4, with all 

















Table 3.4: The proportion of the area compared to length in shortened chromatography runs 
mmol NaCl Percentage of maximum area (%) 
% of peak 90 80 70 60 
0 98.5 96.8 94.6 92.2 
50 99.5 98.4 96.4 93.4 
100 98.9 97.1 94.3 90.6 
170 99.8 99.1 97.9 95.7 






Chapter 4: Separation of Equine Plasma by Ethanol Precipitation 
 
The second key technique examined was ethanol precipitation, because of its common use within the 
blood plasma industry. Because there has been a lack of examination of the basis of the ethanol levels, 
this was carried out. In addition, an examination of the Kistler-Nitschmann technique was carried out 
to test its compatibility with equine plasma. 
 
4.1 Materials and equipment 
 
The blood plasma was sourced in the same way as the samples in Chapter 3. In addition, analytical 
grade sodium acetate (Merck KGaA) was purchased in solid form and concentrated acetic acid (Merck 
KGaA) and ethanol (Sigma Aldrich) was purchased in liquid form.  
 
The AKTA Explorer liquid chromatography systems from Chapter 3 were used in the chromatographic 
applications. Benchtop electronic balances were used to measure the masses of all Eppendorf tubes 
and contents. 
 
4.1.1 Buffer Preparation 
 
1500 mM NaCl and 200 mM sodium acetate stock solutions were prepared, with acetic acid used to 
adjust the pH to 5.2. These were filtered with 40 µm filters and degassed. This pH was selected because 
of its use within Cohn fractionation. 
 
For chromatography, a 1:10 dilution of this stock solution was taken. The pH was altered to 5.2, and 
the buffer was filtered and degassed. This was used for running buffer in size-exclusion 
chromatography steps. For the ion exchange chromatography, Tris buffer was prepared as described 
in Chapter 3. 
 
4.2 Precipitation test 
 
The first stage was to test the blood plasma for ethanol precipitations to test the impact of initial 
precipitations. Because extremely large ethanol concentrations (up to 70%) had been used 
industrially, it was logical to test the necessity of such high levels. 
 
Blood plasma was defrosted in the same manner as described in Chapter 3. This was pipetted into 




These were mixed at room temperature for two hours before being refrigerated at 4°C overnight. The 
precipitate was removed through centrifugation and the supernatant was pipetted off. The masses of 
the precipitates were as given in Table 4.2. 
 
Masses were measured by first weighing each individual Eppendorf tube before any material was 
placed within it. The masses were then measured complete with all material after being mixed. The 
precipitate was then removed from the suspension by centrifugation and the supernatant was 
removed from the Eppendorf tube by pipetting. The masses of the precipitates were thus calculated 





Table 4.1: Preparation of the blood/ethanol/water mixtures 
Ethanol Concentration (%) 0 10 15 20 25 30 35 40 50 60 70 
Water (mL) 800 700 650 600 550 500 450 400 300 200 100 
Ethanol (mL) 0 100 150 200 250 300 350 400 500 600 700 
Blood plasma (mL) 100 100 100 100 100 100 100 100 100 100 100 
Buffer (mL) 100 100 100 100 100 100 100 100 100 100 100 
 
 
Table 4.2: The masses of the precipitates of the blood plasma 
Ethanol concentration (%) 0 10 15 20 25 30 40 50 60 70 
Mass of precipitant (mg) 17.7 37.4 19.5 25.2 35.2 45.4 83.2 76.9 81.1 96.3 
Mass of complete mixture (mg) 170.1 174.9 172.5 172.5 172.3 172 171.3 174.9 173.6 175.1 





Preliminary chromatography in combination with the mass data displayed in Table 2 demonstrated 
that 50% and above levels resulted in little difference in the mass of the precipitates. For this reason, 
these were discontinued and smaller ethanol levels were tested instead. The supernatant was run on 
a Superdex 200 10/300 GL column (GE Healthcare). The results are as given in Figures 4.1, with the 







Figure 4.1: A demonstration of the effect of increasing ethanol levels with gel showing the 0% 
ethanol profile of the chromatograph. The lanes of the gels are as follows: (1) Protein standard; (2) 
through (8) initial peaks; (9) Protein standard; (10) and (11) Secondary peak; (12) Crossover between 
secondary and tertiary peak; (13) and (14) Tertiary peak; (15) and (16) Protein standard 
 











0 54.14 367.99 1351.86 850.78 
10 66.76 121.09 1194.95 759.43 
20 82.1 0 424.9 431.6 
40 83.64 0 435.42 478.29 
 
In addition, blood plasma samples with the same ethanol concentrations, along with a 30% percent 
fraction, were run on a 1 mL Sepharose Q FF column, using the salt gradient steps already established. 




























7 9.7263 10.291 4.5102 2.6266 0 
20 37.597 37.0608 17.5503 10.9953 7.36 
30 22.0114 21.1355 17.0818 17.0056 10.6137 
 
These experiments were performed again with the precipitate being freeze-dried after the 
supernatant was removed. The masses of these freeze-dried products was recorded and is shown in 
Table 4.5. Figure 4.3 gives a graphical representation of the data. 
 
The other aspect that was checked was the protein concentrations of the supernatants of the resulting 
ethanol precipitations. These were examined using ion-exchange chromatography, with the salt levels 
established previously in Chapter 3. For this, Tris buffer was prepared as in Chapter 3. The results of 
these runs are given in Figures 4.4 through 4.7, with the areas under each curve given in Table 4.6. 











0 0.163 0.001 0.8 0.8 
10 0.165 0.003 1.2 0 
20 0.164 0.002 3 1 
30 0.159 0.007 2.9 0.3 







Figure 4.3: The relationship between the ethanol concentration and the mass of blood plasma 
removed. 
 
Figure 4.4: Ion exchange chromatography of the 0% ethanol reconstituted supernatant 
 

















Figure 4.5: Ion exchange chromatography of the 20% ethanol reconstituted supernatant 
 
Figure 4.6: 30% ethanol supernatant run on ion exchange steps established in Chapter 3 (after 













0 10 % 20 30 % 40 % 
0 4597.4 2715.8 59.1 2772.9 2795.9 60.8 633.51 13.8 
50 4931.9 3233.8 65.6 679.09 1121.7 22.7 737.52 15.0 
100 6379.4 3296.1 51.7 1006.03 2132.2 33.4 737.72 11.6 
170 17369.1 12071.2 69.5 2109.09 6428.2 37.0 3303.14 19.0 
350 9171.3 6595.4 71.9 1195.66 2826.5 30.8 2648.77 28.9 
 
4.3 Albumin separation methods 
 
Separations were trialled using the Kistler-Nitschmann method as a basis. The reason this step was 
selected was because of the high purity of albumin obtained. Even though the yield has been noted 





Sodium acetate buffer was made up as described previously, with the pH kept at 5.2. This buffer was 
mixed with blood plasma and ethanol in the volumes shown in Table 4.7 to obtain an ethanol 
concentration of 19% and the pH was then adjusted to 5.85. This mixture was left overnight at 4°C.  
 
The precipitate was then removed by centrifugation and additional ethanol was added to increase the 
ethanol concentration to 40%. The pH was once again adjusted to 5.85, and after a short period of 
mixing this mixture was left overnight at the same temperature. The precipitated was similarly 
removed and the pH was adjusted to 4.8 for another period of mixing and overnight incubation. 
 
After this stage, these supernatants were run through ion-exchange chromatography in a similar 
manner to the blood plasma in Chapter 3. This was done in an attempt to determine the composition 
of the supernatant rather than for separation purposes. The results are given in Figure 4.8. Gels run 
for the various stages can be seen in Figure 4.9, while the area underneath the curves compared to a 
0% ethanol concentration is given in Table 4.8. It is worth noting that the conductivity of this run was 
modified in an attempt to resolve the non-albumin separations in as timely a manner as could be 
achieved. For this reason, the steps below 120 mM NaCl were not carried out, aside from the original 
0 mM step. 
Table 4.7: The composition of the Kistler-Nitschmann separations. 
Component Quantity (mL) 
Blood Plasma 3.55 
Buffer 0.5 
Ethanol (added at 1st step) 0.95 






Figure 4.8: The effect of the Kistler-Nitschmann process on the profile of the blood plasma. 
 
Table 4.8: The areas underneath each peak and their proportion of the total 
Peaks 1 2 3 4 
Area (mAU*mL) 210 171 104 226 
Proportion 30% 24% 15% 32% 





















Chapter 5.0 Discussion 
 
5.1 Protein identification 
 
While most of the results given from the mass spectrometry experiments did not give specific 
identification of proteins because of difficulties with gel bands having a too low protein concentration 
to identify, equine serum albumin was able to be identified successfully. Its corresponding band can 
be seen in Figure 5.1. Although its position was unsurprising, given the large amount of the protein 
within the gel and its molecular mass, it is still useful to have this as a base with which to compare 
other proteins.  
 
 
Figure 5.1: Equine Serum Albumin band circled in the diluted plasma after MS identification 
 
This identification is important because a number of other proteins can be potentially identified from 
this band. For instance, immunoglobulin bands generally give a distinct pattern that can be seen in 
Figure 5.2. Other proteins can be determined thanks to some prior work in the field. For instance, the 
protein band at around 80 kDa is likely to be transferrin, based on the concentration and the location 
of the molecular weight band [114]. For similar reasons, the band at around 50 kDa that is not 






Figure 5.2: Long separation with protein estimations. The circled proteins match the following: (1) 
Immunoglobulin (2) Immunoglobulins; (3) Transferrin; (4) Antitrypsin; (5) Haptoglobin (6) 
Immunoglobulins 
 
These protein identifications are only educated guesses and it is recommended that they be identified 
with more certainty further work. Given that immunoglobulins, for instance, can be identified this 
suggests a number of separation principles to be used. Immunoglobulins can be seen to elute earlier 
in the ion exchange gels, which means that ion exchange chromatography could be used to separate 
these immunoglobulins. 
 
The key dilemma is that, unlike human plasma, there is not an existing market for large scale 
production of many of these proteins. Haemophilia is not a major veterinary priority for the equine 
industry, and many such factors extracted from human plasma are irrelevant for purification from 
equine plasma, primarily Factor VII. Some proteins may be able to act as substitutes for bovine 
proteins in similar fields, but the scope for these is generally limited to research purposes. This seems 
an extremely limited market for large-scale production. Likewise, the potential applications of 
lactoferrin, a transferrin protein, in nutraceuticals, medicine and food products [149] are limited by 
cultural biases against the consumption of horsemeat. Thus, determining practical uses for what are 
essentially waste products is rather difficult. While some may be used as purified research standards, 
it is difficult to imagine such a level of demand from this sector that justifies the industrial scale 
separation of these on a regular basis. 
 





The salt gradients that have proven effective in bovine plasma were equally useful at separating 
equine plasma. The proteins obtained as shown in Figure 3.2 tended to be similar to their bovine 
counterparts, which is unsurprising. As in Moure [27], immunoglobulins were separated at low ethanol 
levels, while albumin was separated around the 170 mM level. This suggests a means of separation 
that could conceivably be used on a large scale. 
 
The salt gradient steps shown in Figures 3.2 and 3.3 differ in the lower concentration salt steps. The 
key differences involved were in the intermediate proteins. Primarily, antitrypsin was better separated 
with increased salt gradients. However, this is generally not a critical protein for industrial separation, 
meaning that it affected the purities of other proteins more than any other factor. This could be 
rectified by further processing, indicating that this step is somewhat redundant. For this reason, the 
gradients obtained by Moure are most likely preferable, unless purifying antitrypsin is a priority. 
 
The key proteins, as mentioned above, are the various globulin proteins, because these are likely to 
have the greatest commercial value. As their separation is not significantly improved by the increased 
number of steps, this indicates that the additional steps may not be necessary to the process. Likewise, 
the separation of albumin was not substantially improved with the additional steps, and in fact may 
be negatively impacted because of the increased volumes to separate downstream.  
 
This redundancy is magnified by the effect of running an increased number of salt concentrations. The 
additional salt concentrations may mean less process difficulty in separating certain proteins 
downstream, but it is unlikely that there will be significantly fewer separation steps as an overall result. 
In addition, the extra time and buffer needed to run these steps all represent extra costs in an 
industrial process. Thus, unless some significant use for the proteins that the additional salt 
concentrations allow better separation for is found, it is probable that fewer salt steps are likely to be 
more efficient. 
 
5.3 Proteins of interest 
 
Immunoglobulins are clearly shown to elute at lower salt concentrations, with albumin eluting at much 
higher concentrations. This is consistent with data from Moure [27] and the respective pI values of 
the proteins. For a scheme aiming to utilise the use of antibodies or F(ab)2, an ion-exchange processing 
step may be a valid first separation step, as little increase in conductivity is necessary for the elution 
of these proteins. Meanwhile, the higher salt concentrations needed to separate albumin mean that 
that is less suited to this process. eCG is difficult to determine due to its low total within the proteome.  
 
Albumin clearly elutes at higher salt concentrations, primarily at 350 mM NaCl. However, the purity 




are not of commercial value, so removing them through standard means such as heat shock is still 
feasible.  
 
5.4 Process improvements 
 
5.4.1 Buffer use and volume 
 
Reducing the quantity of buffer used in the ion exchange step is a key consideration for adapting it to 
an industrial applications. With a minimum of around 750 mL of buffer used for a 20 mL column and 
2 mL sample, the extremely large amounts of buffer required for separation would create considerable 
additional expense. A 400 L column and sample, for instance, may require 15 000 L of buffer if a 
proportional amount is used. The biggest reason for this use of buffer is the lack of sharp peaks 
obtained, requiring large amounts of tailing that requires a considerable amount of buffer to separate. 
 
The height equivalent of the theoretical plate (HETP) values of the various peaks provides further 
evidence of the excessive use of buffer within the process. With the exception of the initial peak, all 
of the peaks’ HETP values are very low, indicating the extensive tailing of the process. Additionally, 
when the measurement of the HETP is changed to only use the elution length at half of the maximum 
absorbance, the values are dramatically different. The difference in these values is due to the apparent 
changes in the number of theoretical plates, which is again indicative of the effects of peak tailing. 
Table 5.1 shows both chromatography runs (long referring to the set of salt concentrations with the 
longer elution period) with both the width of the full peak and that of the width over half the maximum 
absorbance (represented by W and W1/2 respectively). 
 
Table 5.1: The HETP values for the ion-exchange chromatography runs using full width and width at 











100 mM 130 mM 170 mM 350 mM 
long W 0.98 0.013  0.0048  0.0031 0.00035 0.000024 
long W1/2 0.11 0.0023  0.0016  0.0014 0.000062 0.000015 
Short W 0.98  0.011  0.0049  0.0011 0.00014 
Short W1/2 0.11  0.0025  0.0029  0.00021 0.000016 
 
Attempts can be made to appropriately reducing the elution volume, as shown in Table 3.4. This 
demonstrates the extent of the peak lengths that can be reduced while still retaining much of the 
protein. Although the initial immunoglobulin peak has one of the highest depletion rates per volume 
reduced, it also requires the least volume of the various peaks, meaning that further reducing the 
elution volume is less critical than for other peaks. Furthermore, peaks could be combined to reduce 




processing downstream of this chromatography operation. All of these efforts are ultimately partial 
solutions to the problem of large quantities of buffer, but would also significantly diminish the amount 
of raw materials used in the process. However, in order to reduce the amount of raw materials, 
chromatography should be preferred only when these options are able to be easily carried out or with 
smaller volumes of plasma.  
 
The resolution of the peaks were all fairly similar to each other. However, none were especially high, 
with the highest being 0.31 for the 350 mM peak shown in Figure 3.2. This is far below what is generally 
considered acceptable in industrial levels. The most likely cause of this was that peak tailing was 
extremely evident within the various runs. To check a possible causes of this, a run of only BSA was 
made, under otherwise identical conditions to the equine plasma runs. BSA was selected because of 
its similarity to ESA, which as the dominant protein in equine blood plasma would give the best 
approximation of standard blood plasma.  
 
In this run, tailing was almost entirely eliminated. This strongly indicates that tailing is a specific 
behaviour of the blood plasma as opposed to the column or process. The consequence of this is that 
tailing may be inevitable when processing blood plasma. Improving resolution between the various 
peaks is therefore a matter of improving the sample quality, which may not be possible for raw plasma. 
For this reason, ion exchange chromatography is unlikely to be considered suitable for initial 




Scale-up operations were proven to work, with the same concentrations yielding essentially similar 
results as can be seen by the similarities between Figures 3.1 and 3.2. Of particular note was that the 
length of elution proved particularly long for many of the steps. This length was shortened to avoid 
excessive use of buffer, with negligible effects on the final results. For this reason, further shortening 
may be possible for further scale-up. 
 
Biopharma [128] noted several parameters and their effects on scale-up. Key amongst these is to 
maintain constant linear velocity, length and sample concentration. With pure blood plasma being 
used, sample concentration is unlikely to change outside of individual fluctuations within the donor 
horses. While these can be minimized through means such as consistency of age of the horses, such 
measures were outside the scope of this investigation. Column length was more complex, given the 
comparatively short columns used. As it has been established that most columns have a maximum 
length of 0.2 m, it was decided that that would be sufficient for the total length in a scaled-up model.  
 





Figure 3.5 demonstrates a clear relationship between the size of the samples and the elution fractions. 
This is an indicator that the initial sample size of 10% of the column volume is not at the column’s 
capacity. However, there is a loss of binding capacity evident with the increased sample size. Table 3.3 
shows that the change in the amount of protein eluted at each stage is not directly proportional to 
the change in sample size. 
 
The only fraction of which this may not be a direct representative is the initial peak. These fractions 
are also well below proportional levels, but the key difference is that in each case the UV detection 
limit was surpassed. This indicates that the “missing” protein may not be binding to the column. While 
it is also possible that the noted protein is remaining on the column for the entire process, post-
operation cleaning indicates that that is unlikely. Losing blood proteins in the initial wash stage of 
chromatography is not necessarily a critical impediment to using larger sample sizes by proportion of 
the column volume, but the losses caused by this effect would have to be considered in any use of 
larger scale chromatography. The other factor to consider is that the relationship between the protein 
concentration and the UV absorbance is not linear at higher concentrations. This may contribute to 
the apparent gap in expected and actual concentrations. 
 
Interestingly, the larger volume of plasma seems to indicate the presence of an additional protein 
group. Without the use of gels or some other identification method, it is difficult to determine what, 
if any, proteins are within this secondary peak. It is worth noting that the peak in question has a 
combination of immunoglobulin and albumin present. This means that said split may be simply the 
consequence of better separation between the two. However, the presence of transferrin complicates 
this, making overall conclusions difficult to make. Otherwise, there seem to be few differences in the 
chromatographic profile. This indicates that sample size can be increased easily as part of scale up 
without significant negative effect. 
 
5.4.4 Speed of Elution 
 
Speed of elution was shown to have a minimal impact on the separation. Figure 3.4 shows little change 
in the chromatographic profile despite the altered speed of elution. While there is some tightening of 
bands, there is less significant effect on the maximum absorbance and total protein eluted at various 
stages. This indicates that the chromatographic speed has a minimal impact on the overall separation 
with regard to peak appearance. 
 
However, flow rate was also noted to have a key impact on the pressure of the column. There was a 
positive correlation between the speed of elution and the pressure drop over the column, which will 
be discussed in greater detail. Additionally, an increased speed of elution equates to a faster process 
overall; an obvious distinction, but one that is critical at an industrial level due to the extra cost in 
labour and utilities a longer elution requires. This creates a key dilemma, as an excessive pressure 




compressing the media and reducing the porosity and thus the overall binding area. This would result 




One of the key issues in ensuring scale-up is successful is ensuring that column pressure remains at 
acceptable levels. Over the scale-up that occurred in this thesis, the pressure drop increased greatly, 
with 350 kPa common when running at 240 cm/h, rather near the pressure limit of the column. Figure 
5.3 shows the pressure while being run on 20 mL columns. This compares to only 10 kPa on the 1 mL 
column, at a speed of 250 cm/h. Decreasing the elution flow rate was noted to have reduced the 
pressure drop, but this is not an ideal method at an industrial scale. It was also noted that while linear 
velocity was one of the factors which should be kept constant according to Biopharma’s 
recommendations, industrial columns in other industries are often run at much higher linear 
velocities. 
 
Figure 5.3: A demonstration of typical pressure levels at 20 mL chromatography 
 
The Kozeny-Carman equation is given as Equation 5.1. This relation is considered a reliable indicator 
of scale-up pressure [150]. The key aspect of it is void volume, which is not given by GE Healthcare 
and is difficult to directly measure. To determine this, the pressure drop over the runs was substituted 












  (1) 
 
The voidage obtained was around 0.052, which as an approximation was used for the rest of the scale-
up. Applying this to a column that is 20 cm long (approximately the maximum length of industrial 
columns) and increasing the flow rate to 300 cm/h would give a pressure of around 1 MPa. This 
pressure is not exceptionally high for HPLC, though it is much higher than the levels which are 
recommended for laboratory-scale ion-exchange chromatography.  The most logical method of 
reducing this pressure would be to increase either the voidage within the chromatographic media or 
the particle diameter. Given the availability of larger beads designed for large-scale chromatography, 
particle diameter is the easier parameter to change [151]. This would have the disadvantage of 
reducing resolution, but larger columns and samples tend to reduce the resolution. In addition, little 
change is needed to ensure a column run at the same flow rate would have an acceptable pressure, 
as a particle diameter of 150 µm or more would reduce the pressure drop to levels found in the 20 mL 
chromatography operation. Such sized beads are easily obtainable; GE Healthcare for instance 
advertises certain media with an average 200 µm diameter.  
 
Curling [73] has noted that modern chromatography regularly handles elution speeds up to and 
including 700 cm/h. This is clearly considerably higher than what has been assumed here. Raising the 
speeds to these levels while maintaining the pressure drop established would require increasing the 
particle size to around 220 µm diameter, slightly beyond this average size. It is worth noting that the 
linear velocity is one of the factors advised to be held constant. 
 
Flow rates compare somewhat differently for a larger column. The diameter of the column is the ideal 
aspect to increase, due the smaller effect it has on chromatographic separation. This can be seen in 
Equation 1, where increased column diameter has no effect on the pressure. Equation 2 demonstrates 









  (2) 
 
Using Equation 2, the diameter of a scaled-up column can be determined from the volume of the 
blood and the mentioned change in column length. With a standard process of 2000 L, which is a 
common raw human blood plasma batch [152], a column would have to be 11.3 m in diameter. Such 
a column would be extremely large by industrial standards, further suggesting that this 
chromatography operation is better used when the volume of the inlet is considerably reduced. 
Reducing the inlet volume to around 400 L decreases the required diameter under the same conditions 




of 2 m. However, this would mean that only 6 to 7 parallel columns are required for the same column 
volume, instead of around 30.  
 
5.5 Examination of ethanol concentration effects 
 
One of the key problems found with analysing these precipitations was the ethanol interfering with 
the gel. Many of the high ethanol samples (above approximately 20%) would not run easily on the gel, 
causing the supernatants to appear far more dilute than what they actually were. This mostly affected 
relevant concentrations of the proteins present, particularly those that were less abundant before 
precipitation. However, there are still some indicators of key proteins from the gels, even if 
concentrations are difficult to determine. Chromatography was used partially to avoid the dilution, 
but this was instead affected by the reduction in the base line. In addition, it proved more difficult to 
determine exactly which proteins were precipitating at which stages with chromatography than with 
the gels.  
 
The gel indicated that most proteins were removed from the blood plasma at an equal rate, although 
there were clear problems with the consistency of this with the masses of the various gels. While the 
less common proteins seemed to precipitate first, this may be simply a matter of resolution over any 
chemical factor. The proteins precipitating at no ethanol levels was most likely the cryo-precipitate, 
given that this process had not been carried out prior to the ethanol experiments. 
 
There was a clear correlation between the ethanol levels (with the exception of one outlying point) 
and the amount of precipitant within mass measurements as given in Table 4.2, however. The only 
exception to this was at the upper extremes of ethanol concentration tested, where separation was 
independent to the level of ethanol. This indicated that after a certain point, there is little advantage 
in adding additional ethanol to the solution. Freeze-drying, as anticipated, gave a greater degree of 
accuracy in the trends noticed. Although the relationship was not a linear one, this can be explained 
by to the different proteins’ responses to the ethanol.  
 
The size exclusion chromatography carried out contained two main peaks as shown in Figure 4.1. The 
gels also in this figure indicate that these peaks are albumin and immunoglobulins, a conclusion 
supported by the literature [82]. The reduction of these peaks as the ethanol concentration was 
increased is also consistent with literature and with the rest of the results. More detailed 
interpretations are complicated by the presence of air bubbles within the 20% sample. Interestingly, 
the initial peak increased with increasing ethanol concentration, although the secondary peak 






Chromatographic investigation of the supernatant indicates that the albumin was the most soluble in 
ethanol, with other proteins removed with lower concentrations. This can be seen from the 
chromatographic results of Figures 4.4 through 4.7, which show a distinct decrease in all of the peaks, 
but particularly in the lower salt concentrations which have little to no albumin. This is best seen in 
the difference between Figures 4.5 and 4.6, which shows a dramatic reduction of the non-albumin 
peaks in comparison to the others.  
 
However, analysis of the precipitates also indicated that considerable amounts of albumin were 
present in the precipitate. The reductions of the higher salt concentration peaks support this 
hypothesis. This correlates well with previous work that notes that albumin generally can be purified 
from lower ethanol concentration precipitates. This could be an option for increasing the process yield 
should ESA be a target for further purifications.   
 
The supernatants of the blood plasma showed the same reduction in protein concentration. What is 
more interesting from a practical perspective is the lessened amount of albumin, given that this is 
generally the protein that is targeted to be retained. This retention appeared to drop at higher 
percentages of ethanol.  
 
5.6 Kistler-Nitschmann separations 
 
The results of the Kistler-Nitschmann separations were also affected by the side effects of the ethanol 
in the samples. This can be seen from the chromatography in Figure 4.8, where the calculation baseline 
reduced with increasing ethanol, and from the gel, where difficulties in loading samples resulted in 
the second stage appearing to have a lower protein concentration than the final stage. Given that 
these samples were both obtained from the supernatant, and a precipitate was observed within the 
sample in the final stage, additional protein in the last step that does not appear in the middle is clearly 
not possible. However, it is still possible to determine a number of details from these results. 
 
The gel run indicates that the albumin has been retained in solution far more than any other proteins. 
While the obvious intensity change is partially due to precipitation and slight dilution, the 
immunoglobulin bands are much less intense by comparison to the albumin bands. This indicates that 
the albumin was better retained within the sample, as expected and supported by literature [29].  
 
The chromatography gives slightly different results; however this is affected by the calculation 
software. The two peaks with the highest salt concentration in Figure 4.8, particularly the final one, 
have been shown to have most of the albumin in the ion-exchange experiments already detailed. The 
final peak contained a larger proportion of the total area, but the penultimate peak did not. This may 




precipitated albumin. The low salt peak was dramatically reduced, but the initial peak increased. This 
could be because an increasing number of aggregation within the sample, causing a lack of binding. 
 
One of the factors not tested for was recovery of albumin from the precipitate. Part of the reason for 
this is that ESA is not as commercially valuable as HSA, leaving less incentive to increase yields through 
albumin recovery. There are indications that not all albumin has been retained in the supernatant, 
most notably within the gels. Although this lack of value could be seen as an issue, the separations still 
have value as a method of separating other proteins from albumin, as opposed to the reverse. Should 
albumin need to be extracted, on the other hand, further processing most likely will be needed. This 
is due to the high purity (>95%) generally required for research, which is the biggest market for ESA. 
With heat shock being commonly used, this may be an option although there may be increased costs 
due to the higher volume of raw material.  
 
5.6.1 Scale-up  
 
Unlike chromatography, scale up was not directly tested, partially because of the considerable 
literature on similar technologies at an industrial level. The largest challenge with this is the 
fundamentally different methods of mixing. Because of the size of the samples, mixing could be carried 
out by rotating the entire container, while industrially impellers are preferred due to cost. However, 
testing was carried out at a number of different scales, ultimately giving some perspective, although 
the degree of difference was considerably lower (5x maximum) than the chromatography scale-up. In 
addition, some options can be determined from the literature. 
 
The biggest impact that scale-up had was in the mixing stages, which took considerably longer with 
larger volumes. There did not appear to be any other negative effect on the results. Part of the reason 
for this is that the method did not have to be altered for any of these steps. With larger volumes, the 
method used may change and result in a considerably larger impact on separation.  
 
While transferring to a larger tank would be a challenge, particularly in terms of ensuring that the 
impeller would not negatively affect the proteins, this could well be overcome. Thus, ethanol 
precipitations are more likely than ion-exchange chromatography to be a good initial step due to 
easier operation at higher volumes. Interestingly, few investigations centre on tank reactor scale up 
in the context of blood plasma. There is a wealth of literature on scale up of stirred tank bioreactors 
instead, which share many characteristics with precipitation tanks. However, there are several 
advantages in separating blood plasma over other common aspects of bioreactors. The most obvious 
is that oxygen transfer, traditionally a key concern, is unnecessary because no direct chemical 
reactions are taking place. The largest concern is potential damage to the proteins, which can be 
reduced with a large impeller at a low rotational velocity. The key advantage ethanol precipitation has 




for chromatography, allowing for a much lower cost in large scale use. This perhaps indicates the 
suitability of ethanol precipitations for an initial stage of separation. 
 
For a 2000 L batch, a tank of around 1.15 m diameter and 2.88 m height would be sufficient to provide 
plenty of room and conform to an effective diameter to height ratio. This would require a 0.3 m 
impeller that causes a low shear force on the fluid. For instance, a marine impeller may be appropriate. 
However, this tank would be around 3000 L, considerably larger than required. The height, for 
instance, could realistically be reduced to 2.30 m without major effect on the mixing ratio, giving a 
volume of around 2070 L. This is perhaps a little small, giving little room for potential spillage. 
However, the foaming that is traditionally a concern for bioreactors is not an issue here, meaning less 
margin for this will be required. 
 
5.7 A universal separation method for equine plasma  
 
The critical element to this study was to establish a potential method for separation of whole horse 
plasma. Both ethanol precipitations and ion-exchange chromatography have been shown to do this. 
Technical issues, however, tend to favour precipitation, as it is easier and cheaper to scale up than 
chromatography. This can be seen by the volumes of buffer required for the chromatographic 
separation of blood. Though ethanol precipitations have been primarily used for albumin purification 
as seen in the literature, uses in separation for immunoglobulins have also been clearly demonstrated. 
As with any separation, scale up is an issue; however the challenges faced are far fewer than that of 
chromatography. For these reasons, chromatography should be used as a secondary step after any 
precipitations, in order to reduce the volumes and thus costs of operation. However, there were also 
issues found with the purity of products, particularly from one-stage separations.  
 
As previously mentioned, Burnouf has noted the use of cryo-precipitation at the initial stage of human 
blood plasma separation. Unless fibrinogen is a target of separation, it is unlikely that this technique 
would be of any assistance for horse plasma. Few other proteins can be easily obtained from cryo-
precipitation that are likely to have any commercial applications. An ethanol precipitation step is more 
cost-effective, as the proteins separated are far more valuable. Primarily, this precipitation step should 
aim to separate immunoglobulins as quickly as possible, due to their increased value and separation 
at lower levels of ethanol and chromatography.  
 
 
5.7.1 Immunoglobulin waste recovery scheme 
 
The key to an immunoglobulin production process is identifying the proteins available that will give 




be able to be separated with some ease. Notably, the techniques normally used for immunoglobulin 
separation are not conductive to the activity of other proteins, meaning that any changes to 
techniques will likely have to be used as initial steps. 
 
IEC would be an outstanding first step, should the scale of operation be around 500 L or less. An 80 
mM NaCl concentration would allow for near total separation of Ig immunoglobulins from other blood 
products, meaning that all others could be processed as necessary while the immunoglobulins are 
either precipitated or run through affinity chromatography. However, this would be extremely 
expensive in terms of volume and quantities of buffer consumed if this were a first step with a much 
larger plasma volume. 
 
A classic example of a process to adjust would be from Simisiriwong [87]. In this, the first step was a 
pepsin digestion at pH 7.4 using a Tris buffer. Ideally, similar conditions could be achieved from a 
chromatography step, due to the similarities in the buffers. Thus the first operation could be 
chromatography as described, should this prove economically viable. The immunoglobulins eluted 
could then be further purified using the techniques already established in the mentioned study. 
Meanwhile, other proteins such as ESA could be obtained by using greater concentrations of NaCl 
later in the elution. 
 
Were these techniques to prove inadequate due to cost and scale restrictions of chromatography, 
other methods could be trialled. Ethanol precipitations, particularly at low concentrations similar to 
Cohn fractionation, are a prime candidate for separating large volumes of plasma, while retaining 
activity in all other proteins. There are two key disadvantages with this method however; a 
requirement to fundamentally change the immunoglobulin process already established and the 
difficulty in removing all solution from the precipitate. This effect can be seen from the results in 
Tables 4.2 and 4.5, which demonstrate a clear difference in masses after freeze-drying. Even though 
an equal interpretation of these results is that freeze-drying can successfully remove the excess 
precipitate, this operation would be expensive to repeatedly carry out on a large scale. For these 
reasons, chromatography should be preferred if it proves practical at the scale demanded.  
 
Figure 5.4 provides an example of how to separate each aspect of the blood plasma. Part A 
demonstrates this with the use of ethanol precipitation, while Part B indicates how this would be 
undertaken with ion exchange chromatography. Key to this will be identifying where exactly eCG is 
eluted under these conditions, as this will affect the process steps after the ion exchange 





Figure 5.4: A schematic of potential modifications to immunoglobulin purification using a) ethanol 
precipitation and b) ion exchange chromatography  
 
5.7.2 eCG waste recovery scheme 
 
As previously noted, the first step in this process is generally an ethanol precipitation, somewhat 
simplifying the issue of waste protein recovery. Because a 20% ethanol cut would allow most of the 
immunoglobulins to be easily obtained from the precipitate, little change needs to be made to the 
initial operation. To recover the immunoglobulins from this, the precipitate could be resolubilised and 
processed by means such as ammonium sulphate precipitations. However, an IEC step could be added 
after this stage to further purify the immunoglobulins for preparation if necessary. Avoiding excessive 
buffer solution in the precipitate is once again a key concern. 
 
Albumin is a more challenging prospect, due to its retention in both stages of the initial precipitation. 
However, the later operation of an extremely high ethanol concentration could be undertaken at a 
lower ethanol concentration, which would allow for both the retention of albumin, while reducing the 
raw material needs of the operation. However, this is a much lower priority than retaining 





This would give a scheme as shown by Figure 5.4 in Part A. The scheme listed is in many ways the most 
natural of the various combination methods, as there is no requirement of a step prior to current 
operating practices. In each case, additional proteins can simply be purified from the already existing 
waste. The biggest disadvantage, aside from the difficulty in obtaining ESA, is the harsh conditions that 
are generally used for eCG purification. This may result in the loss of activity of some proteins; however 
given that these are currently simply disposed of it will likely take major losses of activity to render 
the methods completely impractical.  
 
5.7.3 Albumin waste recovery scheme 
 
Most ESA commercially available is currently produced by heat shock. In the absence of a large scale 
shift in the production method of albumin, it is difficult to see how to obtain alternative proteins from 
this waste in any reliable fashion. This is because the heat shock method relies specifically on the 
deactivation of all other proteins, relying on a stabilising agent to avoid this occurring to albumin. 
Although this step could be delayed until after earlier separation methods, doing so would render the 
advantage of the lack of unnecessary steps entirely moot.  
 
A shift to existing ethanol methods may help rectify this. Even though this is a dramatic change from 
the previous method, the ubiquity of ethanol precipitation in human plasma indicates that this may 
be a more cost-effective strategy. In this instance, a Kistler-Nitschmann method adaption may prove 
the best strategy. To retain as many proteins as possible, the 19% precipitate could be then be 
resolubilised and have immunoglobulins purified from the resulting solutions. Similar methods could 
be applied to the later precipitations to retain eCG. While this is a highly speculative method, the 
harshness of current methods make an almost entirely new strategy necessary. The supernatant could 
then be treated as normal for an albumin separation. 
 
5.7.4 Initial process 
 
Although these techniques could be used in an attempt to improve existing processes, this is of less 
assistance to those attempting simply to separate raw plasma as a first step. Therefore, it makes sense 
to examine the entire process with no particular protein in mind, to examine the best method for a 
hypothetical start-up. 
 
Once again, precipitation methods are generally the best to begin with, aside from cryo-precipitation. 
For this reason, a Kistler-Nitschmann initial separation is the best to begin with. The 19% supernatant 
could then be used for albumin and eCG purification, while the precipitate could then be used for 
immunoglobulin production. This supernatant could be best resolved by additional steps of the Kistler-
Nitschmann process, allowing for the separation of the eCG from albumin. These could then be 




exchange chromatography could be used to separate the albumin, should heating the volume of 
material prove too expensive for this separation. Meanwhile, the 19% precipitate could be solubilised 
again and separated by the method of choice in order to obtain the relevant immunoglobulins.  
 
On the other hand, there is no large scale demand for ESA at this point in time. Although there are 
markets for it in research areas, this is unlikely to sustain the influx of product that large-scale 
production would provide. This implies that the production of this in large volumes is unnecessary. 
However, this could instead be replaced by some being produced to sell for the research industry. 
 
 
5.8 Future directions 
 
One of the key advantages blood plasma processing has had over other downstream processes is the 
absence of upstream processes involved. This has both ensured consistency in the input material and 
allowed a focus on the downstream steps that has been absent in other processes until recently. The 
result of this is a large number of precipitation methods being present for use. However, this 
advantage has been coupled with the lack of development in new processes. 
 
The problems with ion exchange chromatography are evidence of this lack of new processes. One of 
the themes of the combined methods is that ion exchange chromatography requires considerable 
attention to factors such as pressure drop, uses large amounts of buffer and is difficult to optimise. 
These issues all make this form of separation less feasible, despite the fact that it has been shown to 
give clear separations. If membrane chromatography, for instance, were to be successfully developed, 
this may remove a large number of these problems. This would significantly alter the techniques that 
could be considered optimal. 
 
The other point to consider is the applications of the proteins available. A key example of this is 
albumin, which is currently not extensively used from equine plasma, but is from human plasma. This 
may become more able to be used as the costs of downstream processing decrease. For this reason, 
it is critical to consider the existing applications of parallel proteins. Most of these proteins are clotting 
factors, which are less likely to see extensive use.  
 
ESA has some potential to be used more extensively in the future. Unlike human albumin, it is not 
used for medical purposes because of a lack of economic incentive. However, as downstream 
processing of blood plasma becomes less expensive, this may change. Using the techniques already 
established may therefore be useful for production. Fibrinogen may also see use as a coagulation 






Much of this relates to the expense of downstream processing. Innovation in the use of alternative 
proteins is unlikely to become more common until the methods of separation become cheaper. 
Likewise, companies will not reduce their waste outflows if processing them for further proteins is not 
seen as profitable. Consequentially, there needs to be considerable movement towards more modern 






Chapter 6: Conclusions and future directions 
 
The understudied nature of equine plasma has resulted in considerable amounts of waste being 
generated through the process because of the small number of proteins available. However, no efforts 
have been made to separate the blood plasma comprehensively, which was what this thesis 
attempted to show. 
 
Ion exchange chromatography was demonstrated to separate blood with repeatable results and a 
degree of purity, particularly with regard to immunoglobulins. Because these are the most valuable 
proteins generally available, this gives a clear direction of separation. Even though a direction for scale 
up has been obtained, there are still a number of issues surrounding the use of chromatography on a 
large scale. In particular, the large use of buffer restricts the usability due to the potential costs. If 
these can be reduced through means such as smaller samples, cheaper techniques relying on the same 
principles or some other development, then this would be an ideal method. However, some work is 
still required in determining effective salt levels for better separation of albumin. 
 
Ethanol precipitations, on the other hand, provide a far cheaper method for separation, although less 
effective than ion-exchange for immunoglobulins. These also have the advantage of utilising 
equipment most likely present in any industrial processing plant, as opposed to the more specialised 
requirements of chromatography. The biggest disadvantage is that from the method tested, albumin 
is the best separated, which is one of the least valuable proteins normally commercially separated. 
 
One of the key limitations of this process is the lack of proteins separated from equine plasma. 
Increased research in downstream techniques and their adoption in industry may result in better use 
of this resource, but it is of note that the blood plasma industry has already taken a large number of 
steps to improve this. Precipitation steps are far more common and better explored within this than 
in other industries [153, 154]. Although membrane technologies are being heavily explored, there is 
still no guarantee that these will prove adaptable to the blood plasma industry. This places limitations 
on the strategies that can be obtained for the production of many of these proteins. 
 
However, the advantages of the separation system determined is its conformation with current 
technologies while retaining the ability to be adapted as new technology arrives. New proteins 
determined may result in alterations in this method. Given that this may well come from low 
concentration proteins, it is difficult to predict precisely which processes will be optimal to separate 
these. Fortunately, the current system is fairly robust, with little damage being done to other proteins 
and thus any new proteins will likely be able to be separated from the stages already established. 
 
Although the lack of waste processing was originally seen as a critical issue to be overcome, evidence 




when purified. However, as the production of downstream processing units becomes cheaper, many 
more proteins will become more likely to be produced due to the reduced economic disincentive. A 
key advantage of the methods trialled in this thesis is that they are often used industrially, which 
would reduce the costs further if existing equipment is being used. 
 
The key areas of research in the future must therefore be to examine other proteins within the 
proteome to determine their effectiveness in veterinary or other applications. Developments in 
downstream technologies, particularly in chromatographic effectiveness, are also necessary. While 
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Appendix A: The data for the chromatography run shown in Figure 4.1 
 
Comparison of ethanol precipitations. Data for each below 
Table A1: The raw data of the 0% ethanol concentration curve in Figure 4.1 
Volume point (mL) Area (mAU*mL) Maximum peak height (mAU) 
-4.01 1.4522 288.356 
-3.77 1.2020 7.394 
-3.61 4.3870 6.351 
0.27 1.0340 3.324 
0.97 1.0246 3.765 
1.78 1.4082 4.327 
2.07 1.8414 4.432 
3.00 2.1137 5.528 
3.14 1.7265 5.753 
4.00 1.0322 8.458 
7.03 4.0663 106.258 
8.45 54.1435 110.693 
9.38 367.9850 351.409 
12.89 1351.8614 1169.629 
14.47 850.7763 904.813 
19.36 12.9426 16.045 
21.63 12.0456 17.949 
23.56 14.6414 22.098 
25.41 14.1278 18.426 
27.79 2.1176  3.173 
      
Total number of detected peaks  73 
Total area (mAU*ml)  2708.5530 
Area in evaluated peaks (mAU*ml)  2701.9292 
Ratio peak area / total area  0.997554 
Total peak width (ml)  19.17 
Column height (cm)  30.00 
Column V0 (ml)  8.00 




Baseline  S200 BYPASS 291015001 0PC001:10_UV1_280nm@01,BASEM 
Peak rejection on    
 Maximum number of peaks ()  20 
 
 
Table A2: The raw data of the 10% ethanol concentration curve in Figure 4.1 
Volume point (mL) Area (mAU*mL) Maximum peak height (mAU) 
-4.01 0.0112 2.251 
-3.97 0.0675 2.649 
-3.82 8.7661 12.041 
-1.83 0.8836 3.343 
-1.64 0.8868 3.325 
-1.33 1.2324 3.303 
-0.92 0.9979 3.313 
-0.65 0.9907 3.326 
-0.26 1.3483 3.361 
8.48 66.7633 110.536 
9.48 121.0857 112.557 
12.91 1194.9544 1001.413 
14.46 759.4330 766.014 
19.40 0.5247 1.625 
20.97 0.0059 0.093 
21.67 0.1882 1.092 
23.27 8.3455 7.210 
24.07 5.3404 8.698 
24.42 9.8066 9.368 
26.24 11.2169 8.979 
      
Total number of detected peaks  24 
Total area (mAU*ml)  2192.8653 
Area in evaluated peaks (mAU*ml)  2192.8490 
Ratio peak area / total area  0.999993 
Total peak width (ml)  18.69 
Column height (cm)  30.00 
Column V0 (ml)  8.00 




Baseline  S200 BYPASS 291015002 10PC001:10_UV1_280nm@11,BASEM 
Peak rejection on    
 Maximum number of peaks ()  20 
 
 
Table A3: The raw data for the 20% ethanol concentration curve in Figure 4.1 
Volume point (mL) Area (mAU*mL) Maximum peak height (mAU) 
-3.81 2.6534 7.298 
0.42 1.6304 3.493 
8.45 82.1012 109.446 
13.05 289.8503 373.702 
13.35 135.7308 534.204 
14.62 283.9453 340.186 
15.37 150.7489 650.799 
19.48 1.0769 1.878 
21.17 0.9302 2.290 
21.81 4.1095 83.346 
21.98 5.8883 94.548 
22.16 4.8974 106.257 
22.34 9.5270 155.730 
22.54 7.5928 179.055 
22.86 7.9120 180.052 
23.09 10.2126 138.940 
23.82 37.6859 260.904 
24.30 0.9115 3.802 
24.93 3.1564 4.508 
25.85 2.4260 3.102 
      
Total number of detected peaks  109 
Total area (mAU*ml)  1051.8460 
Area in evaluated peaks (mAU*ml)  1042.9869 
Ratio peak area / total area  0.991578 
Total peak width (ml)  16.33 
Column height (cm)  30.00 
Column V0 (ml)  8.00 




Baseline  S200 BYPASS 291015003 20PC001:10_UV1_280nm@13,BASEM 
Peak rejection on    
 Maximum number of peaks ()  20 
 
Table A4: The raw data for the 40% ethanol concentration curve in Figure 4.1 
Volume point (mL) Area (mAU*mL) Maximum peak height (mAU) 
-3.77 1.2295 2.862 
0.25 0.6860 1.767 
0.62 0.3361 1.346 
7.85 83.6428 86.586 
12.96 435.4159 397.594 
14.46 478.2894 300.845 
19.32 7.4597 8.637 
21.02 3.7063 6.651 
21.52 0.3715 2.251 
23.63 0.6617 2.258 
23.94 0.3838 1.828 
24.28 0.5508 2.481 
24.41 1.1075 2.717 
26.77 0.7038 1.895 
26.94 0.3866 1.585 
27.37 0.6512 1.525 
28.17 0.4282 1.460 
28.80 0.3204 2.413 
29.22 1.2821 3.660 
29.30 1.3170 3.767 
      
Total number of detected peaks  50 
Total area (mAU*ml)  1021.7789 
Area in evaluated peaks (mAU*ml)  1018.9304 
Ratio peak area / total area  0.997212 
Total peak width (ml)  18.69 
Column height (cm)  30.00 
Column V0 (ml)  8.00 
Calculated from  S200 BYPASS 301015005 40PC001:10_UV1_280nm 




Peak rejection on    




Appendix B: Kistler-Nitschmann separation data 
 
Table B1: The chromatographic profile of the Kistler-Nitschmann separation with tabulated peaks 
and area underneath the curve 
Volume point (mL) Area (mAU*mL) Maximum peak height (mAU) 
-2.06 6.6974 25.334 
-1.32 1.6206 1.561 
0.74 26.3628 7.394 
17.70 202.9837 15.486 
38.16 7.2652 1.410 
62.84 171.0630 6.960 
164.15 12.8873 3.616 
170.22 43.8064 3.847 
177.41 12.8727 3.191 
181.59  7.7546  2.769 
184.81  4.2094  2.340 
186.61  9.9157  2.148 
192.16  3.0498  1.595 
193.90  2.6197  1.455 
195.86  3.1754  1.231 
198.76  2.2209  1.001 
201.56  1.6860  0.833 
363.23  226.0455 22.667 
462.05  2.6811  0.904 
464.64  3.5122  0.959 
      
Total number of detected peaks  140 
Total area (mAU*ml)  771.1657 
Area in evaluated peaks (mAU*ml)  752.4294 
Ratio peak area / total area  0.975704 
Total peak width (ml)  175.09 
Column height (cm)  10.00 
Column V (ml)  18.60 
Calculated from  alb checker kn method001:10_UV1_280nm 
Baseline  alb checker kn method001:10_UV1_280nm@01,BASEM 
Peak rejection on    




Appendix C: Mass measurements of the Eppendorf tubes and precipitates 
 
All measurements in grams unless otherwise noted 
 




1 2 3 
0 1.014 1.029 1.017 
10 1.04 1.034 1.013 
20 1.007 0.991 1.014 
30 1.014 1.012 1.014 
40 1.039 1.014 1.011 
 




1 2 3 
0 1.177 1.193 1.179 
10 1.208 1.197 1.176 
20 1.169 1.156 1.178 
30 1.166 1.171 1.179 
40 1.202 1.173 1.172 
 





1 2 3 
0 1.063 1.085 1.067 
10 1.096 1.074 1.053 
20 1.047 1.043 1.056 
30 1.074 1.065 1.063 













1 2 3 
0 1.016 1.031 1.017 
10 1.042 1.036 1.015 
20 1.012 0.996 1.017 
30 1.018 1.017 1.019 
40 1.046 1.02 1.019 
 




1 2 3 Average 
mass 
Uncertainty 
0 0.163 0.164 0.162 0.163 0.001 
10 0.168 0.163 0.163 0.165 0.003 
20 0.162 0.165 0.164 0.164 0.002 
30 0.152 0.159 0.165 0.159 0.007 
40 0.163 0.159 0.161 0.161 0.002 
 




1 2 3 Average 
mass 
Uncertainty 
0 0.049 0.056 0.05 0.052 0.004 
10 0.056 0.04 0.04 0.05 0.01 
20 0.04 0.052 0.042 0.045 0.007 
30 0.06 0.053 0.049 0.054 0.006 
40 0.069 0.068 0.077 0.071 0.006 
 




1 2 3 Average 
mass 
Uncertainty 
0 0.002 0.002 0 0.001 0.001 
10 0.002 0.002 0.002 0.002 0 
20 0.005 0.005 0.003 0.004 0.001 
30 0.004 0.005 0.005 0.005 0.001 












1 2 3 Average 
proportion 
Uncertainty 
0 1.2% 1.2% 0.0% 0.8% 0.8% 
10 1.2% 1.2% 1.2% 1.2% 0.0% 
20 3.1% 3.0% 1.8% 3% 1% 
30 2.6% 3.1% 3.0% 2.9% 0.3% 
40 4.3% 3.8% 5.0% 4.3% 0.7% 
 




1 2 3 Average 
proportion 
Uncertainty 
0 4% 4% 0% 3% 3% 
10 4% 5% 5% 5% 1% 
20 13% 10% 7% 10% 3% 
30 7% 9% 10% 9% 2% 
40 10% 9% 10% 10% 1% 
 
 
 
 
 
